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ABSTRACT 
 
In developed countries, cancer is one of the major causes of death, along with cardiovascular 
diseases. One of the main reasons that can be attributed to this high mortality is the failure of 
current treatment options. The hard distinction of normal and cancer cells, but also the 
phenomenon of resistance and the inefficacy to treat metastases, are the main obstacles when 
treating cancer patients. 
Gemcitabine (2,2-difluorodeoxycytidine), commercially available as Gemzar® by Eli Lilly and 
Company, is a nucleoside analogue which has been proven efficient against a wide range of solid 
tumors. The use of gemcitabine hydrochloride was approved in 1996 by the Food and Drug 
Administration (FDA) as first-line treatment for patients with locally advanced (non-resectable 
Stage II or Stage III) or metastatic (Stage IV) pancreatic adenocarcinoma previously treated with 
fluorouracil (5-FU). Gemcitabine is activated in vivo via phosphorylation of its 5-hydroxyl group to 
gemcitabine monophosphate by deoxycytidine kinase, and is subsequently phosphorylated by 
intracellular kinases to the triphosphate form. However, gemcitabine may be deaminated to its 
inactive uridine metabolite, 2,2-difluorodeoxyuridine, by cytidine deaminase (CDA), which is 
present at high levels in both human plasma and liver. 
This project aims at the chemical modification of gemcitabine and subsequent conjugation to 
Cell-Penetrating Peptides (CPPs), in an effort to both prevent (or retard) deamination of that drug 
and facilitate its delivery into cancer cells, taking advantage of the fact that all CPPs are able to 
efficiently pass through cell membranes while being non-cytotoxic and carrying a wide variety of 
cargos inside cells. 
Two CPP-drug conjugates have been successfully synthesized, purified and characterized by 
HPLC and LC-MS. The time-dependent kinetics of gemcitabine release from hydrolysis of these 
new conjugates was studied in phosphate-buffered saline (PBS) at physiological pH and 
temperature. Furthermore, the biological activity of these two new conjugates was evaluated 
against three different human tumoral cell lines: MKN-28 (human gastric cancer), Caco-2 
(heterogeneous human epithelial colorectal adenocarcinoma) and HT-29 (human colon 
adenocarcinoma). 
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RESUMO 
 
Nos países desenvolvidos, o cancro é uma das principais causas de morte, juntamente com as 
doenças cardiovasculares. Uma das razões fundamentais que pode ser atribuída à elevada 
mortalidade desta doença é a baixa taxa de sucesso das opções terapêuticas atualmente 
disponíveis. O tratamento de doenças oncológicas enfrenta alguns obstáculos, como a difícil 
distinção entre células saudáveis e células tumorais (que conduz a sérios efeitos secundários 
associados à terapia), mas também o aparecimento de fenómenos de resistência a 
quimioterapêuticos e a ineficácia do tratamento de metástases. 
A Gemcitabina (2,2- difluorodesoxicitidina) é um análogo de nucleósido comercializado pela 
farmacêutica Eli Lilly and Company como Gemzar® cuja atividade contra uma grande variedade 
de tumores sólidos foi já extensivamente comprovada. O uso de cloridrato de gencitabina foi 
aprovado em 1996 pelo órgão governamental dos Estados Unidos da América responsável pelo 
controlo dos alimentos e medicamentos (Food and Drug Administration, USA) como opção 
terapêutica de primeira linha para doentes com adenocarcinoma pancreático localmente avançado 
(inoperável, fase II ou II) ou metastático (fase IV) previamente tratados com 5-fluorouracilo (5-FU, 
um outro análogo de nucleósido). A gencitabina é ativada in vivo por fosforilação na posição 5- a 
monofosfato de gencitabina pela enzima desoxicitidina cinase, e é subsequentemente fosforilada 
por outras cinases intracelulares à forma trifosfatada, que tem capacidade de inibir a síntese de 
ADN. No entanto, a gencitabina também pode ser inativada, sendo convertida no metabolito 
uridínico pela enzima citidina desaminase, presente em elevados níveis no plasma e fígado 
humano. 
Com este projeto pretendeu-se modificar quimicamente a gencitabina e subsequentemente 
conjugar o seu derivado a Péptidos Penetradores Celulares (CPPs), esperando que estes novos 
pro-fármacos consigam aumentar a entrada deste agente nas células cancerígenas, tirando 
partido da propriedade intrínseca dos CPPs, péptidos capazes de atravessar eficazmente 
membranas celulares, podendo transportar para o interior de diferentes tipos de células inúmeras 
moléculas, sem comprometer a integridade da membrana. 
Foram sintetizados dois conjugados FármacoPéptido, que foram purificados e caracterizados 
por Cromatografia Líquida de Alta Pressão e por Espetrometria de Massa acoplada a 
Cromatografia Líquida de Baixa Pressão. A cinética de libertação de gencitabina na sua forma 
livre foi estudada em condições fisiológicas e foi ainda avaliada a atividade biológica destes novos 
conjugados contra três linhas tumorais humanas: MKN-28 (cancro gástrico), Caco-2 e HT-29 
(provenientes do cólon).  
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OBJECTIVES 
OBJECTIVES 
 
The main goal of the work developed in this thesis was the development of new gemcitabine 
prodrugs, obtained through chemical modification of that anticancer agent, followed by conjugation 
of the modified derivative with Cell-Penetrating Peptides Penetratin and pVEC, activated with an N-
terminal cystein residue. 
Cys-Penetratin: C-RQIKIWFQNRRMKWKK 
Cys-pVEC: C-LLIILRRRIRKQAHAHSK 
  
Furthermore, the work also aimed at the study of the time-dependent kinetics of gemcitabine 
release from hydrolysis of the new conjugates under physiological conditions. 
 
Gemcitabine  Linker  Penetratin 
Gemcitabine  Linker  pVEC 
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1. INTRODUCTION 
1.1. Cancer Management 
In developed countries, cancer is one of the major causes of death, along with cardiovascular 
diseases. This condition involves the abnormal growth of any type of cell with the potential to 
invade or spread to other parts of the body. One of the main reasons that can be attributed to the 
high mortality of this group of diseases is the failure of current treatment options. The hard 
distinction between normal and cancer cells and difficulty in targeting only the altered cells, the 
phenomenon of resistance, and the inefficacy to treat metastases are the main obstacles when 
treating cancer patients. 
Cancer management and treatment plans depend on several factors, such as the type, location, 
and grade of the cancer as well as the patients health and personal choices. Treatments may be 
curative or aimed at improving life quality. There are many treatment options for cancer, including 
surgery, chemotherapy, radiotherapy, hormonal therapy and palliative care. 
Although surgery is the primary method used in most isolated solid cancers and is often an 
important part of determining the definitive diagnosis, chemotherapy is a major treatment choice. 
This type of therapy is recurrently used in combination with hormonal therapy (pharmacotherapy) 
and with other cancer treatments, such as radiotherapy, surgery, and/or hyperthermia therapy. 
Chemotherapy consists on the administration of chemical substances, especially one or more anti-
cancer drugs (chemotherapeutic agents), which are traditionally cytotoxic agents, killing cells that 
divide rapidly, one of the main properties of most cancer cells. However, these substances will also 
reach other cells in our body that divide rapidly under normal circumstances, as cells in the bone 
marrow, digestive tract, and hair follicles. This can lead to various severe side effects, frequently 
associated with chemotherapy. These adverse reactions in addition to the limited effectiveness of 
oncologic treatments make the development of new therapeutic options that are able to be more 
selective and effective an imperative need. 
Alternative targeted therapies have been put forward, aiming at efficiently treating specific types 
of cancer while decreasing the severe side effects associated with these treatments. According to 
the National Cancer Institute of the United States of America (NCI, USA), targeted therapies are 
deliberately chosen or designed to interact with and act on specific molecular targets that are 
associated with cancer, whereas most standard chemotherapies act on all rapidly dividing normal 
and cancerous cells (many standard chemotherapies were identified because they kill cells) [1]. 
These targeted therapies are often cytostatic (that is, they block tumor cell proliferation), whereas 
standard chemotherapy agents are cytotoxic (that is, they kill tumor cells). 
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Still, there are some limitations to targeted therapeutic approaches: cancer cells can become 
resistant to them and, for this reason, targeted therapies may work best in combination; another 
current limitation of targeted therapies is that drugs for some identified targets are difficult to 
develop because of the targets structure and/or the way its function is regulated in the cell. 
Moreover, although targeted therapies are designed to reduce side effects, some patients 
receiving this type of therapy suffer from substantial adverse effects, the most common including 
diarrhea and liver problems, such as hepatitis and elevated liver enzymes. Nevertheless, several 
experimental targeted therapies for specific types of cancer are currently being studied in clinical 
trials and some have already been approved by the Food and Drug Administration (FDA). 
 
1.2. Gemcitabine 
The current treatment of cancer using chemotherapy is largely based on the use of nucleoside 
analogues and gemcitabine, or 2!,2!-difluorodeoxycytidine (1, Figure 1), is one of such analogues. 
Despite the similarities with other nucleoside analogues, gemcitabine has many distinctive 
properties, including its spectrum of activity. 
Gemcitabine is commercially available as Gemzar® and was developed by the pharmaceutical 
Eli Lilly and Company in the 1980s. Although gemcitabine was originally investigated for its 
antiviral effects [2], this drug has been proven efficient against a wide range of solid tumors and 
has since been developed as an active agent for cancer therapy. The FDA has also approved the 
use of gemcitabine (a) in combination with carboplatin for the treatment of advanced ovarian 
cancer that has relapsed at least 6 months after completion of platinum-based therapy [3]; (b) in 
combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior 
anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically 
contraindicated [4]; (c) in combination with cisplatin for the treatment of non-small cell lung cancer 
(NSCLC) [5] and (d) as a single agent for the treatment of pancreatic cancer [6]. Gemcitabine is 
particularly effective against pancreatic cancer, and the use of its hydrochloride salt was approved 
by the FDA in 1996 as first-line treatment for patients with locally advanced (non-resectable Stage 
II or Stage III) or metastatic (Stage IV) pancreatic adenocarcinoma previously treated with 
fluorouracil (5-FU) [7]. 
However, treatment with gemcitabine leads to some severe adverse reactions, which are 
dependent on dosage and duration of the treatment, clinical indication and cancer stage, gender, 
age and patients clinical history. The most common include myelosuppression, hepatic and renal 
toxicity, cardiovascular alterations (such as hypotension, capillary leak syndrome,) 
nausea/vomiting, fever, thrombocytopenia and dyspnea [8]. 
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Figure 1: Chemical structure of Gemcitabine (2!,2!-difluorodeoxycytidine), where 4-(N)- and 5- sites are highlighted. 
1.2.1. Biodistribution and Mechanism of Action 
Gemcitabine is a polar drug with low membrane permeability, and is primarily administered by 
intravenous infusions. It has a very short plasma circulation time and the elimination half-life 
depends upon the infusion time, age and gender of the patient, ranging from 42 to 94 min for short 
infusions and from 4 to 10 h for infusions of 70 min [9]. An increased toxicity is associated with 
longer infusions and, at higher doses, major toxicity can be observed, such as neutropenia, 
reversible hepatic transaminase increase and high levels of hepatoxicity, renal toxicity, 
myelosuppression, thrombocytopaenia, anemia, proteinuria, nausea and vomiting, mild flulike 
syndrome, and mild skin rash. Also, gemcitabine is rapidly cleared from the body upon its 
enzymatic conversion in the blood, liver, kidney, and various tumor tissues [10, 11]. 
Upon administration, gemcitabine is transported in the plasma and crosses the plasma 
membrane into cells via nucleoside transporters. These transporters can be sodium-dependent 
(human concentrative nucleoside transporter, hCNTs) or sodium-independent (human equilibrative 
nucleoside transporter, hENTs) [12]. There are two equilibrative nucleoside transporters (hENT1 
and hENT2) and three concentrative nucleoside transporters (hCNT1, hCNT2, and hCNT3). 
Kinetic studies have shown that gemcitabine intracellular uptake is preferentially directed by 
hENT1 and, to a lesser extent, by hCNT1 and hCNT3 [13, 14]. Also, several studies have shown 
the importance of the presence of the hENT1 transporter for an optimal response to gemcitabine 
[15]. 
Once inside the cells, gemcitabine needs to be activated, and undergoes a series of 
phosphorylation steps catalyzed by intracellular enzymes (Figure 2). First, deoxycytidine kinase 
(dCK) phosphorylates gemcitabine to a monophosphate derivative, dFdCMP. Then, nucleoside 
monophosphate kinase (UMP/CMP) phosphorylates dFdCMP to gemcitabine diphosphate 
(dFdCDP) and finally diphosphate kinase yields gemcitabine triphosphate (dFdCTP), the active 
form of this drug [16]. 
 4-(N)-site 
5- site  
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Figure 2: Mechanism of intracellular activation of gemcitabine. Adapted from [17]. 
 
However, gemcitabine can also be inactivated inside cells. This inactivation is due to the 
conversion of gemcitabine into its inactive uridine metabolite, 2,2-difluorodeoxyuridine (dFdU), 
catalyzed by cytidine deaminase (CDA), as well as to the deamination of gemcitabine 
monophosphate into dFdUMP, which is catalyzed by deoxycytidylate deaminase (DCTD). 
Furthermore, the phosphorylated metabolites of gemcitabine are inactivated via reduction by 
cellular 5-nucleotidase (5-NT). CDA is present at high levels in both human plasma and liver, and 
the enzymatic conversion of gemcitabine rapidly clears it from the body [16]. 
In its triphosphate form, dFdCTP, gemcitabine acts as an antimetabolic drug, being a 
competitive substrate of deoxycytidine triphosphate to DNA polymerases, and causes cell death by 
apoptosis. This action is possible because of the analogy between dFdCTP and deoxycytidine 
triphosphate: gemcitabine triphosphate is incorporated into DNA during replication (making it an S-
phase-specific drug) thus inhibiting chain elongation of DNA because DNA polymerases are 
unable to proceed after one deoxynucleotide is added [18]. This action is called masked chain 
termination, and it appears to lock the drug into DNA because proof-reading exonucleases are 
unable to remove gemcitabine nucleotide from this penultimate position [19]. The inhibitory action 
of gemcitabine is further improved by its nondetection in the DNA chain. 
Additionally, because the diphosphate form of gemcitabine (dFdCDP) inhibits ribonucleoside 
diphosphate reductase (RNR), an enzyme of DNA synthesis which permits the formation of 
nucleoside triphosphates, there is a significant decrease in the concentration of cellular 
deoxycytidine triphosphate (dCTP) and a change in the ratio of dCTP/dFdCTP in favor of dFdCTP. 
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The accumulation of gemcitabine triphosphate and the intracellular reduction of dCTP results in the 
inhibition of dFdCMP inactivation by DCTD, which requires sufficient concentrations of dCTP to be 
active [20]. Active metabolites of gemcitabine can also inhibit ribonucleotide reductase (RR), dCMP 
deaminase, and CTP synthetase, thus enhancing gemcitabine activation, due to a unique property 
called self-potentiation.  
 
1.2.2. Resistance to Gemcitabine 
The rise of drug resistance is a major obstacle in the treatment of many forms of cancer, and 
this phenomenon usually appears very rapidly after the beginning of the treatment, when cells are 
typically sensitive to the drug. It is critical to have a better understating oh this phenomenon so that 
drugs can be replaced by more efficient substituents, combination therapies can be developed or 
the targeting of the drugs can be improved. 
There are many factors contributing to the development of resistance to gemcitabine, from 
transporters expression to abnormal levels of the enzymes involved in the activation, metabolism 
and mechanism of action of gemcitabine. One of the major causes of resistance to gemcitabine 
can be attributed to alterations in transporters. hENT1 is a preferential transporter and studies 
have found a strong correlation between gemcitabine resistance and a deficiency of hENT1 
expression in human breast and pancreatic cancer cells [21, 22]. Additionally, studies have shown 
that the determination of hENT1 but also hCNT3 expression can be used as a prognostic marker 
for patients treated with gemcitabine [23, 24]. 
There are many enzymes involved in the metabolism of gemcitabine, and alterations on the 
expression levels of any of these enzymes can make cells resistant to this drug or, on the other 
hand, make it more cytotoxic. One of the key enzymes is deoxycytidine kinase (dCK), responsible 
for the first phosphorylation of gemcitabine. This is the rate-limiting enzyme involved in the 
metabolism of gemcitabine and its expression has been postulated to correlate with gemcitabine 
resistance [25]. This can be caused by mutations of the dCK gene [26] or by low levels of dCK 
enzyme activity [27]. Also, high levels of the catabolic enzymes cytidine deaminase (CDA), dCMP 
deaminase and 5!-nucleotidase (5!-NT) are associated with resistance to gemcitabine [28]. 
Another factor in gemcitabine resistance is the overexpression of ribonucleotide reductase (RR) 
[29]. This enzyme is mainly responsible for the conversion of ribonucleosides to 
deoxyribonucleoside triphosphates (dNTPs), which are essential for DNA polymerization and 
repair. Both regulatory subunit RRM1 and catalytic subunit RRM2 influence the cytotoxic action of 
gemcitabine. RRM1 overexpression through transfection of a lung cancer cell line resulted in 
gemcitabine resistance and the reduction of RRM1 expression through RNA interference 
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abrogated the induced gemcitabine resistance [30]. As for the RRM2 subunit, its overexpression is 
associated with resistance to gemcitabine and down regulation of RRM2 by siRNA enhanced 
gemcitabine cytotoxicity, both in vitro and in vivo in pancreatic adenocarcinoma [31]. 
The aberrant expression of genes associated with cellular survival and apoptosis upon 
treatment with gemcitabine is also implicated in resistance to this drug [32, 33]. Once gemcitabine 
is incorporated into DNA, the cell enters a process of cell death, mainly through apoptosis, in 
response to cytotoxic drug treatment [34, 35].  One of the main proteins involved in the cell death 
mechanism and apoptosis is p53 [36]. The expression of p53 plays an important role in apoptosis 
pathways, inducing cell cycle arrest and in the higher concentration ranges, p53 induces apoptosis. 
In sensitive malignant cells, a variety of anticancer drugs have been shown to produce extensive 
apoptosis, but it has been suggested that the inability of some cells to undergo apoptosis is similar 
to the mechanism of gemcitabine resistance. Human lung cancer expressing the mutation of the 
p53 gene does not undergo apoptosis after gemcitabine treatment [37].  
 
1.2.3. Modifications of Gemcitabine 
From the previous sections it can be inferred that, although gemcitabine is an effective 
treatment to patients with different types of cancer and mainly to treat pancreatic adenocarcinoma, 
it has low membrane permeability and is extensively degraded by CDA into an inactive metabolite 
in the liver. Moreover, the increasing levels of resistance also reduce gemcitabine cytotoxicity. 
Thus, a frequent administration schedule at high drug doses is required, and this leads to serious 
side effects. To date, various innovative approaches have been developed to overcome these 
disadvantages, including combination therapy to determine the utility of adding a second cytotoxic 
drug or radiotherapy to this treatment regimen, but clinical trials have shown modest improvements 
in disease-free survival, and did not result in statistically significant improvements in survival with 
reported survival rates reaching 20% to 40% at 1 year [38, 39]. The FDA has also approved the 
use of gemcitabine in combination with carboplatin, paclitaxel and cisplatin for the treatment of 
patients with ovarian, breast and non-small cell lung cancer (NSCLC), respectively. 
A different strategy consists on chemically modifying gemcitabine, in order to enhance transport 
and cytotoxicity. These modifications can provide (i) protection against deamination, (ii) better 
storage and (iii) prolonged release in the cell, (iv) a possible use in the case of deoxycytidine 
kinase deficiency, and (v) transporter deficiency. These new gemcitabine-based systems have the 
potential to improve the clinical outcome of a chemotherapy strategy and make these new 
molecules into prodrugs (a biologically inactive derivative of a parent drug molecule that usually 
requires an enzymatic or chemical transformation within the body to release the active drug and 
has improved delivery properties in comparison to the parent molecule [40]). 
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 Most modifications on the gemcitabine structure are performed at the 4-(N)- and 5-positions, 
as these two functional groups have significant roles in the action of this drug: the inactivation of 
gemcitabine results from deamination on the 4-(N)-site, whereas the necessary phosphorylation to 
make it active occurs in the hydroxyl group at the 5-position. Some of the new molecules resulting 
from the modification of gemcitabine and their most relevant properties are described below. 
 
1.2.3.1. Modifications at the 4-(N)-site of gemcitabine 
1.2.3.1.1. PEG  Gemcitabine 
Polyethylene glycol (PEG, Figure 3) refers to a family of differently-sized polymers with high 
solubility in water and excellent biocompatibility that have been conjugated to several molecules, 
from antitumor agents, proteins, peptides or low molecular-weight drugs, due to a relevant number 
of advantages resulting from the PEGylation process [41]. This technique has become the leading 
approach to (a) increase plasma half-life of the PEGylated products, (b) provide enzyme protection 
and (c) accumulate the PEGylated product in tumor zones according to the enhanced permeability 
and retention effect (EPR) [42-44]. However, PEG can activate the complement system, which 
has been recently proposed as a major underlying or contributing cause of infusion reactions, 
referred to as complement activation-related pseudoallergy (CARPA), an anaphylactic-type 
reaction within the Type I category of hypersensitivity reactions (HSRs) [45]. Clinical trials of 
several derivatives of PEG coupled to anticancer drugs are already under way or have been 
completed [46]. 
 
Figure 3: Chemical structures of polyethylene glycol (PEG) and of a PEG  gemcitabine conjugate. 
Because of encouraging results from studies with other anticancer agents, and given that the 
anticancer effects of gemcitabine are limited by its rapid metabolization and consequently short 
half-life, as well as its low tumor uptake, the coupling of PEG to gemcitabine has been tested by 
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several research teams. In a recent paper, the synthesis of a PEG  gemcitabine construct, by 
conjugating the amino group at the 4-(N)-position of gemcitabine to an N-hydroxysuccinimide 
derivative of PEG, has been carried out (Figure 3) [47]. It is known that the cellular uptake of PEG-
drug conjugates occurs through endocytosis and that conjugates are retained in transport vesicles 
which traffic along the endolysosomal scaffold, which are acidic in nature [48, 49]. The 
endolysosomal transport vesicles allow cleavage of the amide bonds between PEG and 
gemcitabine, thanks to the acidic nature of these vesicles, and thereby allow its prolonged release. 
Vandanas team was able to demonstrate a colocalization of PEG-gemcitabine in lysosome and 
endosome after 24 h incubation, and an enhanced retention in cancer cells after 3 days of 
incubation in comparison to parent gemcitabine, using confocal analysis. Moreover, 
pharmacokinetic studies have shown consistently higher (by 21-fold)  bioavailability of PEG-
gemcitabine over unmodified gemcitabine, after 1 h of intravenous administration in mice and, in 
MiaPaCA 2 and PANC-1 cells, PEG  gemcitabine was more effective in comparison to native 
gemcitabine. 
 
1.2.3.1.2. Folate-PEG  Gemcitabine 
Folate, or folic acid, has been used as a targeting agent in cancer nanotherapeutics, because 
its receptor is overexpressed in several types of cancers (lung, breast, kidney, and ovarian) [50-
52], while in normal human tissues its receptors may have limited distribution. To improve the 
effect of PEG  gemcitabine, folic acid has been inserted into PEG  gemcitabine conjugates, 
where the drug was coupled through its 4-(N)-amino group to the carboxylic end of an 
aminocarboxylated PEG (NH2-PEG-COOH), while folic acid was linked through its carboxylic 
function to the amino group of the polymer ( 
Figure 4). The active targeting and cytotoxic superiority of Folate-PEG  Gemcitabine, 
compared to the nontargeted PEG  gemcitabine, were investigated [53]. All conjugates were able 
to release the drug in a pH-dependent manner with no role played by enzymes, which confirms 
previous studies showing that the protection of the amino group of gemcitabine prevents enzymatic 
degradation [54]. Polymer conjugation of gemcitabine increased drug plasma half-life by reducing 
its kidney clearance, which was dependent on the polymers molecular weight. Folic acidPEG 
derivatives were also found as less toxic than PEG derivatives, which was explained by a slower 
entry into the cell by endocytosis and a cytotoxic activity only after the release of gemcitabine. 
Moreover, derivatives targeting folate receptors need a receptor-mediated endocytosis mechanism 
for cell penetration in cells that do not overexpress the folate receptor. In contrast, in KB-3-1 cells, 
which overexpress folate receptors, derivatives with folate are certainly less cytotoxic than parent 
gemcitabine but are more cytotoxic than gemcitabine only coupled to PEG [53]. 
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Figure 4: Chemical structure of a Folate-PEG  gemcitabine conjugate. 
 
1.2.3.1.3. Valproic acid  Gemcitabine (LY2334737) 
An orally available prodrug of gemcitabine has been developed, consisting of gemcitabine 
linked to valproic acid via an amide bond at the 4-(N)-position. This molecule is called LY2334737 
(Figure 5), and is able to circumvent the rapid deamination of gemcitabine into dFdU, and thus 
bypass hydrolysis in enterocytes and portal circulation, avoiding the extensive first pass 
metabolism that occurs with unmodified gemcitabine, underlying its poor oral bioavailability due to 
an extensive deamination by CDA. 
The stability of the prodrug was tested on a pH range from 1 to 8, to check the possibility of 
delivering an intact prodrug into systemic circulation after passing through the gastrointestinal tract 
following oral administration. LY2334737 degradation is pH-dependent, with about 21% 
degradation at pH 1 and no degradation between pH 6 to 8, after 4 h of incubation at 40 °C [55]. 
Circulating levels of LY2334737 are detectable several hours after oral administration. In addition, 
a gradual release of gemcitabine following cleavage of the amide bond should enhance efficacy, 
since more cancer cells should be exposed to a continuous effective cytotoxic level of gemcitabine. 
The researchers have found that, in mice bearing HCT-116 human colon tumor xenografts, a much 
smaller dose via oral administration has the same efficacy that a high dose administered via 
intraperitoneal injection. Phase I trials of LY2334737 either as monotherapy or in combination with 
other agents were carried out to determine the maximum tolerated dose and dose limiting toxicities 
of daily administration [56]. 
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Figure 5: Chemical structure of LY2334737, a prodrug of gemcitabine tested in Phase I clinical trials. 
 
1.2.3.1.4. Squalenoyl  Gemcitabine 
Squalene is a triterpene that is an intermediate in the cholesterol biosynthesis pathway. Both in 
vitro and in vivo model experiments suggest a tumor-inhibiting role for squalene [57] and, 
therefore,  it has been linked to various nucleoside analogues [58]. 
Couvreurs team was interested in the pharmacological activity of gemcitabine covalently 
coupled at 4-(N)-position with 1,1,2-tris-nor-squalenoic acid to obtain Sq-gemcitabine [4-(N)-tris-
nor-squalenoyl-gemcitabine, SQdFdC] (Figure 6). 
 
 
Figure 6: Chemical structure of squalenoyl  gemcitabine (SQdFdC). 
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Those authors investigated the anticancer activity of Sq-gemcitabine in vitro on resistant murine 
and human leukemia cells (L1210 10K and CEM/ARAC8C, respectively). L1210 10K cells were 
characterized by a lower expression of cytoplasmic dCK and CEM/ARAC8C by a deficiency in 
hENT1 transporters [59, 60], hence respectively representing two major resistance factors to 
gemcitabine. After 72 h of incubation at different concentrations, Sq-gemcitabine demonstrated 
3.26 and 3.22-fold higher cytotoxicity compared to gemcitabine with L1210 10K and 
CEM/ARAC8C, respectively [60]. After intravenous injection of Sq-gemcitabine in aggressive 
leukemia-bearing mice, a significant increase in survival time compared to gemcitabine was 
obtained. This increase was attributed to the high degree of localization of Sq-gemcitabine in the 
liver and spleen, which are the major metastatic organs. Sq-gemcitabine was found to be more 
efficient than gemcitabine, suggesting the considerable potential of this treatment for leukemia. 
Studies on human pancreatic adenocarcinoma models were also performed. Sq-gemcitabine 
showed higher antiproliferative and cytotoxic effects in vitro compared to parent gemcitabine, on 
chemoresistant tumor cells (Panc-1) and sensitive cell lines (Capan-1 and BxPc-3), which were 
associated with significant DNA synthesis inhibition, S-phase arrest, and higher induction of 
apoptosis (caspase 3 activation) [61]. 
While the mechanism of entry and metabolization of gemcitabine into cells is known, the cellular 
uptake mechanism of Sq-gemcitabine, its subcellular localization, and its metabolization pathway 
have been studied only recently. An in vitro passive entry in cancer cells (MCF-7: human breast 
adenocarcinoma) and a preferential accumulation in endoplasmic reticulum, thanks to the high 
lipophilic level of squalene, were observed [62]. This passive input may explain the efficacy of Sq-
gemcitabine on cell lines deficient in active transporters [63]. 
Finally, two important elements have contributed to the efficiency of this new drug: (a) the 
storage of gemcitabine in the endoplasmic reticulum allowed it to be protected from deamination by 
the presence of squalene in the 4-(N)-position, and (b) the progressive cleavage to its parent form 
allowed the metabolization of the cancer compound. 
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1.2.3.1.5. Lipophilic Prodrugs 
To protect against the deamination of gemcitabine, it was proposed to covalently link the amino 
group in the 4-(N)-position with saturated and monounsaturated fatty acids, namely, with those 
bearing long C18 and C20 chains. In 1998, Eli Lilly patented the synthesis of lipophilic gemcitabine 
derivatives (Figure 7), which showed better cytotoxicity than unmodified gemcitabine. 
 
 
Figure 7: General structure of lipophilic 4-(N)-acyl  gemcitabine conjugates. 
 
A few years later, the synthesis of a series of 4-(N)-acyl derivative prodrugs of gemcitabine was 
carried out, first to prevent diffusion through liposome bilayers and later to be encapsulated into 
other particles [64]. Liposomal formulations containing these lipophilic prodrugs of gemcitabine 
increased the drug entrapment efficacy with respect to conventional liposomes, but their 
encapsulation efficiency (EE) closely depended on the length of the 4-(N)-acyl chain, the 
phospholipids, and the presence of cholesterol. Better results were obtained by incorporating 4-
(N)-lauroyl-gemcitabine (GemC12) and 4-(N)-stearoyl-gemcitabine (GemC18) in liposomes 
composed by DSPC/DSPG 9:1. Furthermore, while parent gemcitabine is rapidly converted into 
inactive metabolite by CDA which is widely distributed in plasma, C12 and C18 derivatives were 
both stable in plasma. After 24 h, more than 60% of unmodified GemC12 and GemC18 prodrugs 
were still present, whereas only 40% of unmodified gemcitabine was present after 8 h of incubation 
of the drug in plasma. The prodrugs were also stable the pH range 4!9, which confirms the 
stability of the acyl-drug amide linkage. In vitro studies have shown that cytotoxicity of free or 
encapsulated GemC12 and GemC18 derivatives were 2- and 7-fold (in KB and HT-29 cells line, 
respectively) greater than that of parent gemcitabine. Encapsulation of the C18 derivatives into 
liposomes produced an increase of plasma availability: the AUC was 50 times higher than for 
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unmodified gemcitabine, resulting in the increased accumulation in tumor cells and a high level of 
antitumoral efficacy in mice grafted with HT-29 and KB 396p cells [65]. 
The increase of anticancer activity observed with these lipophilic derivatives compared with 
parent gemcitabine was obtained at the expense of their solubility in aqueous media. Indeed, with 
their highly lipophilic properties, these compounds proved difficult to reconcile with intravenous 
administration, and hence encapsulation is necessary. The modification of lipophilic behavior and 
encapsulation could be considered a good and versatile antitumoral approach against several 
tumors which become less sensitive to the parent drug. 
 
1.2.3.1.6. HGemcitabine: Hoechst conjugated to gemcitabine  
Dasari and his team developed a new conjugate, composed of the DNA binding agent Hoechst 
conjugated to gemcitabine [66, 67]. HGemcitabine ( 
Figure 8) is designed to reduce the systemic toxicity of gemcitabine by targeting it to the 
necrotic core of tumors, and also protect against deamination of its 4-(N) amine via protection with 
an amide bond. HGemcitabine targets tumors via its Hoechst moiety, which binds extracellular 
DNA (E-DNA) present in the necrotic core of tumors. The authors showed that HGemcitabine is 
significantly more effective than free gemcitabine at treating xenograft human colon tumors in nude 
mice, and also has a maximum tolerated dose equivalent to that of gemcitabine [67]. 
 
 
 
 
Figure 8: Chemical structure of Hoechst  Gemcitabine. 
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1.2.3.2. Modifications at the 5-site of gemcitabine 
1.2.3.2.1. CP4126 
In an attempt to enhance cellular uptake, prolong cell retention, and increase the half-life of 
gemcitabine with a less hydrophilic moiety, conjugation with a fatty acid side chain at the drugs 5-
site has also been carried out [68, 69]. In this connection, CP4126 has been developed through 
esterification of the 5-position of the nucleoside sugar moiety with elaidic acid, a monounsaturated 
fatty acid with a trans-double bond at carbon 9 (Figure 9). 
 
Figure 9: Chemical structure of gemcitabine derivative CP4126. 
 
Due to its different molecular design, CP4126 is absorbed by cancer cells independent of 
hENT1 levels, which improves its efficacy in tumors with low or no hENT1 expression [70]. CP
4126 needs to be converted into gemcitabine by nonidentified esterases, releasing the fatty acid 
and allowing the free drug to be phosphorylated [71].  In vitro tests have shown that IC50 of 
gemcitabine increased up to 200-fold in deficient nucleoside transport cell lines, but there was no 
difference with CP4126, suggesting a nucleoside transporter-independent transport in the cell of 
the fatty acid derivative [72]. Inside the cell, CP4126 was localized in the membrane and the 
cytosolic fraction, leading to long retention after removal of the cell culture medium. This 
accumulation caused a slower and prolonged release of the gemcitabine from the lipophilic 
derivative.  CP4126 is active in cells with deficient nucleoside membrane transport [73], but on 
the other hand, activity of parent gemcitabine and CP4126 was comparable in the cell lines 
without resistance, while in dCK deficient cells, both compounds were inactive, because CP4126 
depends, like free gemcitabine, on activation by dCK. 
In contrast to parent gemcitabine, which was highly toxic via the oral route, CP4126 was 
administered orally with various schedules and an efficient antitumor activity [74]. CP4126 is 
currently in a phase II clinical trial with patients with solid tumors [71], to investigate the use of CP
4126 as a second-line treatment for advanced, metastatic pancreatic cancer in patients refractory 
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to first line gemcitabine treatment, where the resistance mechanism is likely due to impaired drug 
entry into tumor cells. 
1.2.3.2.2. NEO6002 
NeoPharm has synthesized a novel gemcitabine-cardiolipin conjugate via a succinate linker to 
enhance the uptake and efficacy by a prolonged release of gemcitabine in cancer cells [75]. 
Cardiolipin (CL) is a major membrane phospholipid specifically localized in mitochondria. At the 
cellular level, CL has been shown to have a role in the triggering of apoptosis [76]. The conjugate 
is called NEO6002 (Figure 10) and in vitro studies showed that this conjugate can improve 
cytotoxic efficacy and potentially overcome NT-deficient (nucleoside transporters) gemcitabine-
resistant tumors, indicating a different internalization route of NEO6002 [77]. NeoPharms studies 
on NEO6002 showed evidence of cytotoxicity against various cancer cell lines, including A549 
(human lung), BxPC-3 (human pancreas), MX-1 (human breast), HT-29 (human colon), and P388 
(murine leukemia) [78]. In vivo studies showed that mice treated with gemcitabine for six daily 27 
"mol/kg-doses were all moribund, whereas no mouse treated with NEO6002 died. This suggested 
that NEO6002 was less toxic at equimolar dosage when compared to gemcitabine. 
 
 
Figure 10: Chemical structure of NEO6002. 
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1.2.3.2.3. Phosphoramidate Gemcitabine 
Because the obligatory phosphorylation is often the rate-limiting step in the activation process of 
many anticancer drugs and is therefore still one of the limiting factors for the therapeutic use of 
nucleoside analogues, the use of modified nucleotide prodrugs incorporating a phosphate 
protecting group, has led to the selective release of the monophosphorylated nucleoside analogue 
[79]. This modification was tested on gemcitabine to get (a) resistance to chemical degradation, (b) 
passive diffusion across cell membranes, and (c) release of the monophosphorylated metabolite, 
independent of kinase expression. These prodrugs were designed to undergo intracellular 
activation to generate an unstable phosphoramidate intermediate anion, followed by a 
spontaneous cyclization and P?N bond cleavage by water to liberate the nucleoside 
monophosphate [80].  
In 2009, Perigaud et al. synthesized four derivatives of gemcitabine, N-(n-butylamino)-O-(S-
pivaloyl-2-thioethyl)-O-5-gemcitabine phosphoramidate diester (Gem-1), N-(isopropylamino)-O-(S-
pivaloyl-2-thioethyl)-O-5-gemcitabine phosphoramidate diester (Gem-2), N-(benzylamino)-O-(S-
pivaloyl-2-thioethyl)-O-5-gemcitabine phosphoramidate diester (Gem-3), and N-(benzylamino)-O-
(S-(2,2-dimethyl-3-hydroxypropionyl)-2-thioethyl)-O-5-gemcitabine phosphoramidate diester 
(Gem-4) (Figure 11). A better cytotoxicity level was obtained in preliminary in vitro tests with Gem-
1, Gem-2, and Gem-3 compared to the parent gemcitabine in L1210 10K cell line (23.7 ± 1.2 "M, 
18.3 ± 1.5 "M, 9.7 ± 9.0 "M, 36.7 ± 11.6 "M, respectively) [81]. 
 
Figure 11: Chemical structures of gemcitabine derivatives Gem-1, Gem-2, Gem-3 and Gem-4. 
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The purpose of these modifications was to overcome resistance in tumors deficient in dCK by 
intracellular delivery of gemcitabine 5#-monophosphate after cell-membrane crossing by passive 
diffusion [82]. In vitro tests on many cancer cell lines have shown that the prodrugs are less active 
than unmodified gemcitabine in wildtype cell lines but more active than the parent drug in dCK 
deficient cell lines (AG6000 and CEM-dCK). However, after blocking the equilibrative nucleoside 
transport, the inhibition of tumor growth was no longer observed with the prodrugs, indicating that 
their antitumor activity was mediated by cell entry implying equilibrative nucleoside transport. 
 
1.2.3.2.4. Gemcitabine prodrugs incorporating D-enantiomer amino acids 
Gemcitabine prodrugs with D- and L-amino acids (Figure 12) were synthesized by Tsumes 
team. Their chemical stability in buffers, resistance to glycosidic bond metabolism, enzymatic 
activation, permeability in Caco-2 cells and mouse intestinal membrane and antiproliferative 
activity in cancer cells were determined and compared to that of parent gemcitabine [83]. 
 
  
Figure 12: Gemcitabine prodrugs with D- and L-amino acids. 
 
As expected, prodrugs containing D-amino acids were enzymatically more stable than their L-
configuration counterparts. The activation of all gemcitabine prodrugs was 1.3  17.6-fold faster in 
cancer cell homogenate than their hydrolysis in buffer, suggesting enzymatic action. The 
enzymatic activation of amino acid monoester prodrugs containing D-amino acids in cell 
homogenates was 2.2-10.9-fold slower than for amino acid monoester prodrugs with L-amino 
acids. All prodrugs exhibited enhanced resistance to glycosidic bond metabolism by thymidine 
phosphorylase compared to parent gemcitabine. Also, these gemcitabine prodrugs showed 
R 
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effective permeability in mouse jejunum to superior to gemcitabine. More importantly, the plasma 
concentration of D-amino acid gemcitabine prodrugs was considerably higher than that of L-amino 
acid gemcitabine prodrugs. 
Overall, gemcitabine has become the standard treatment for pancreatic cancer, and is also 
widely used in combination for other solid cancers such as lung, bladder, ovary, or breast. The 
short half-life is not the only drawback; numerous tumors develop resistance mechanisms: 
resistance by a lack of transporters and resistance by a lack of kinase required for phosphorylation 
and thus activation are some examples. The chemical modification of a drug is a smart solution to 
try to override this resistance and improve the resulting pharmacokinetic parameters. Gemcitabine 
prodrugs have beneficial antitumoral effects by using independent nucleoside transport, by 
reducing the catabolic effect of CDA, by prolonging the release of the native or monophosphate 
gemcitabine, and finally by enhancing the cytotoxicity effect. Thus, gemcitabine modification seems 
to be an innovative and interesting approach to treat less-sensitive cancers. In this connection, this 
thesis explores the chemical modification of gemcitabine and subsequent conjugation to Cell-
Penetrating Peptides (CPP), in an effort to facilitate the delivery of that drug into cancer cells, 
taking advantage of the fact that all CPP are able to efficiently pass through cell membranes while 
being non-cytotoxic and carrying a wide variety of cargos inside cells [84]. The main features of 
CPPs and their chemical synthesis methods are next described. 
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1.3. Cell-Penetrating Peptides  
Today, the treatment and/or cure of genetic diseases, cancer or bacterial infections resistant to 
conventional antibiotics are some of the greatest challenges in the field of medicine. In this context, 
peptides and proteins have been the subject of considerable interest in medicine, research and 
drug development due to a wide variety of applications.  
Within the wide variety of peptides used in todays medicine for innumerous applications, 
Membrane Active Peptides (MAPs) have some particular advantages over small molecules 
because they have higher specificity and affinity for therapeutic targets, but also in relation to 
proteins of greater molecular weight in terms of feasibility of synthesis, derivatization flexibility, low 
immunogenicity and physicochemical parameters compatible with their use as therapeutic agents 
[85]. MAPs include Cell-Penetrating Peptides (CPPs), capable of efficiently delivering 
deoxyribonucleic acid (DNA), proteins, or other molecules to the interior of a variety of cell types, 
via a receptor-independent mechanism while maintaining the integrity of the cell, and Anti-Microbial 
Peptides (AMPs), which interact with bacteria, fungi or parasites, inhibiting their activity by 
destabilizing their cell membranes. 
CPPs have the intrinsic property to deliver therapeutic molecules (nucleic acids, drugs, imaging 
agents, etc.) into cells and tissues in a nontoxic manner. This has indicated that they may be 
potential components of future drugs and disease diagnostic agents. These versatile peptides are 
simple to synthesize, functionalize, and characterize yet are able to deliver covalently or 
noncovalently bound bioactive cargos (from small chemical drugs to large plasmid DNA) inside 
cells, primarily via endocytosis, in order to obtain high levels of gene expression, gene silencing, or 
tumor targeting, for example (Figure 13). Typically, CPPs are often passive and nonselective, and 
must be functionalized or chemically modified to create effective delivery vectors that succeed in 
targeting specific cells or tissues. Furthermore, the design of clinically effective systemic delivery 
systems requires the same attention to detail in both design of the delivered cargo and the cell-
penetrating peptide carrier [84]. 
Several strategies have been developed to deliver therapeutic agents across cellular 
membranes, whose hydrophobic nature protects cells from an influx of exogenous molecules, 
including bioactive molecules such as peptides, proteins, and oligonucleotides. These include 
microinjection, electroporation, and liposome and viral-based vectors. However, these methods 
have various drawbacks, including low efficiency, high toxicity, penurious bioavailability, and poor 
specificity. An alternative strategy emerged from the unexpected finding that short sequences of 
some proteins exerted membrane-crossing properties, including the 16-mer peptide derived from 
the third helix homeodomain of Antennapedia (later named Penetratin) and the 11-mer derived 
from TAT protein. These two peptides served as the foundation for the development of CPPs as a 
new type of molecular vector able to promote the delivery of a variety of cargos. 
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Figure 13: CPPs as delivery vectors  intracellular delivery of CPP-cargo complexes. Reproduced from [84] 
In recent years, CPPs have been extensively studied and their main characteristics have been 
established: low cytotoxicity, ability to be taken up by a variety of cell types, dose-dependent 
efficiency, and no restriction with respect to the size or type of cargo [86]. In general, CPPs are 
relatively short peptides that consist of less than 40 amino acids and are able to enter cells by 
means of various mechanisms, including endocytosis, and are further able to assist in the 
intracellular delivery of covalently or noncovalently conjugated bioactive cargos. 
Understanding the properties and similarities of these peptides is a key factor for the rational 
design and prediction of new CPPs. For example, almost every CPP sequence involves positively 
charged amino acids. In fact, a chain of arginines forms one of the most widely used CPPs, R9 
[87].  The interactions of a given CPP with cell membranes can also be governed by its secondary 
structure, specifically helicity. It has been shown that peptides with an R-helical region can more 
efficiently enter cells [88]. 
When using CPPs as a delivery system, one must consider that drug delivery must often be 
highly specific. This has also become a major issue in the design of CPPs because they tend to 
enter cells nonselectively. The use of a specific drug alleviates this problem, but there are also 
ways to improve the delivery vector. For example, cell-specific peptide sequences have been 
shown to target breast cancer cells [89]. With these promising results, it is possible that CPPs 
could one day emerge as tissue-specific transport vectors for a variety of bioactive molecules [90, 
91]. The greatest challenge will be the design of peptides that have specificity for specific 
glycosaminoglycans (GAGs), lipids or membrane proteins, and thus have the ability to select one 
internalization pathway over another to specifically deliver the cargo to cells or tissues and thereby 
promote its biological activity.  
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1.3.1. Cellular Uptake Mechanisms of CPPs 
Although numerous studies report on the uptake mechanisms that transport CPPs across the 
plasma membrane, the exact pathways through which CPPs enter cells have not been absolutely 
resolved [92, 93]. Despite many similarities among CPPs, the mechanism of their uptake has been 
seen to vary considerably. The use of different experimental conditions can also affect the cellular 
uptake and translocation mechanism of CPPs, as evidenced by contradictory observations. For 
example, contradictory results are obtained through the use of different concentrations, cell types, 
incubation time, and various physiochemical parameters of the CPPs, including hydrophobicity and 
net charge [94-97]. Therefore, it is likely that CPPs without any cargo can be taken up by cells via 
multiple pathways, including direct penetration of the plasma membrane and endocytic uptake 
mediated by clathrin, caveolae, and/or other molecules, depending on the nature of the peptide/cell 
interaction (Figure 14). 
 
Figure 14: Different mechanisms of cellular uptake CPPs can use to penetrate into cells. Reproduced from [98]. 
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1.3.2. Applications of CPPs 
The ability to introduce drugs and other active biomolecules into cells led to investigating the 
potential use of CPPs as therapeutics. A large number of preclinical studies have reported on the 
successful applications of complexes of CPPs attached to therapeutic cargos in cancer, muscular 
dystrophy, cardiology, antiprion diseases, and both viral and bacterial infections [84]. 
For this thesis, CPPs applications in cancer therapy are the most relevant. Therapeutics that 
make use of CPPs have been reported in numerous studies over the last two decades. Properly 
developed CPPs and their conjugates with therapeutics offer a very promising pathway to deliver 
lower concentrations of toxic drugs to critical tissues such as tumors, heart, etc. One drawback in 
the use of chemotherapy is the evolution of drug resistance within the cell population. CPP-drug 
constructs have great potential to increase the solubility, biodistribution, and pharmacokinetic 
profiles of currently approved chemotherapeutic drugs. Small chemotherapeutic drugs have also 
been delivered by CPPs (doxorubicin, methotrexate, cyclosporine A, paclitaxel) [98]. CPP-
doxorubicin conjugates were demonstrated to exhibit a higher apoptotic efficiency compared with 
free doxorubicin in the MDA-MB 231 cell line due to the different apoptotic pathways utilized by the 
CPP construct [99]. 
 
In summary, CPPs are cell-penetrating peptides that can efficiently traverse the plasma 
membrane of both cells and tissues and are successfully used as delivery vectors for therapeutic 
molecules. After efficient cellular internalization, CPPs are able to release their cargo into the 
cytosol in order to promote the desired biological effect. When coupled to a cargo, CPPs use 
endocytosis as the main cellular translocation mechanism. There are several ways to increase the 
uptake and stability of CPP-cargo complexes in vivo, for example, chemical modifications of the 
structure of known CPPs or rational design of novel CPPs. Further investigations into the structure 
and mechanisms of uptake of CPP-cargo complexes will be required to evaluate CPPs as potential 
delivery tools for biomolecules in in vitro and in vivo models. Prior to use, CPPs must undergo both 
pharmacological and toxicological studies in vivo. Considering evidence from numerous studies, 
CPPs have the potential to become a universal tool to carry therapeutic molecules across cellular 
membranes without a risk of toxicity or inflammatory reactions. 
For the research developed within scope of this thesis, peptides Penetratin 
(RQIKIWFQNRRMKWKK) and pVEC (LLIILRRRIRKQAHAHSK) were selected. Penetratin was 
selected because of its historical significance: it was one of the first CPPs to be discovered and 
has been extensively studied, including in cancer research [100, 101]. The second peptide, pVEC, 
equally displays an excellent penetration capability and has been applied to cancer treatment as 
well [89, 102, 103]. pVEC was chosen for this project due to its sequence similarity to Penetratin, in 
an attempt to determine the importance of the sequence and size of the peptides in their activity. 
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1.3.3. Solid Phase Peptide Synthesis (SPPS) 
Given the importance and the enormous therapeutic potential of peptides, there is a growing 
need to obtain them in the necessary quantities and purity degrees for their application in the 
clinics. Although peptides can be extracted from biological matrices (cells, tissue or even 
organisms for example), and can also be attained recurring to recombinant DNA expression 
techniques in microorganisms, these approaches do not yield, in a general sense, peptides in 
quantities sufficient enough nor with the degree of purity required for therapeutic use. 
The chemical synthesis of peptides is the only methodology that allows structural modifications 
of peptides with a look toward the improvement of their therapeutic index, whether it is through 
incorporation of unnatural amino acids or other chemical alterations. Additionally, the chemical 
synthesis generally provides peptides in an even larger scale and with a higher degree of final 
purity. Therefore, several methodologies have been developed to chemically synthesize peptides. 
Initially, this type of synthesis was exclusively carried out in solution phase. However, this 
methodology presents several disadvantages  it is extremely costly, time consuming, complex 
(each intermediary needs to be isolated and purified) and has low returns. In an effort to overcome 
these limitations, in 1963, Robert Bruce Merrifield introduced Solid Phase Peptide Synthesis 
(SPPS), a new method of synthesizing peptides that presents innumerable advantages relative to 
the peptide synthesis in solution. The peptide is built on an insoluble solid support and the reaction 
vessel contains a filter and is, normally, connected to a vacuum system. This allows the removal of 
side products formed and excess of reagents and solvents by washing and filtration. Consequently, 
the elongation of the peptide up until the sequence is complete is done in a continuous way, and 
the isolation and purification of the peptide is carried out only once, after cleaving the peptide 
(separating it from the solid support). 
Briefly, in order to synthesize peptides, $-amino acids (AA) are sequentially linked together 
through the formation of an amide bond (peptide bond). The condensation reaction must be 
regioselective, being absolutely necessary to suppress the reactivity of functional groups other 
than those involved in the formation of the peptide bond, that is, the carboxyl group of AA1, the $-
amino group of AA2 and reactive functional groups possibly present in side chains of amino acids 
must be blocked in some way. The reactivity of the $-amino group is suppressed by a temporary 
protecting group, removed after each coupling (usually 9-fluorenylmethoxycarbonyl (Fmoc) or tert-
butoxycarbonyl (Boc)), and the carboxyl group of AA1 as well as any other reactive functional 
groups in AA side chains are blocked by permanent protection, respectively, through the bond 
linking the peptide to the solid support or the peptide bond or by permanent protecting groups 
(tert-butyl (tBu) or benzyl (Bzl)), respectively. These permanent protecting groups are removed 
when the peptide sequence is completed and the peptide is subjected to a chemical treatment to 
cleave it from the solid support [104]. 
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Also, and because the reaction between an amino group and a carboxyl group is 
thermodynamically but not kinetically favored, it is necessary to properly activate the carboxyl 
group. This activation is achieved with coupling agents, also known as condensation or activating 
agents. Otherwise, an undesired acid-base reaction will occur leading to the formation of a salt, 
instead of the intended condensation reaction, bonding the two amino acids through an amide 
bond. 
By convention, the sequential order of amino acids in a peptide is presented in the Nt % Ct 
sense, i.e., with the N-terminal amino acid (Nt, with the free $-amino group) on the left and the C-
terminal amino acid (Ct, with the free carboxyl group) on the right. However, chemical synthesis is 
performed in the Ct à Nt sense (contrary to the biosynthetic route for protein synthesis in 
ribosomes). So, in SPPS, a peptide is constructed following cycles of activation and coupling of N-
protected amino acids and deprotection steps, starting with the Ct amino acid through the Nt amino 
acid (Figure 15). When the sequence is complete, a chemical cleavage is performed to remove the 
permanent protecting groups and to separate the peptide from the solid support. 
In addition to the innumerous advantages of the SPPS methodology (it is much is faster, simpler 
 and therefore cheaper  and has better yields than peptide synthesis in solution), the SPPS 
approach was quickly and easily automated (also by Merrifield and collaborators in 1965). Since 
then, new equipments have been developed, aiming at producing peptides faster and more 
efficiently. Some equipments can even synthesize different peptides simultaneously (in a small or 
median scale). One example of these equipments is the Symphony X Multiplex Peptide 
Synthesizer, developed by Protein Technologies, Inc. ©, which is a 24-channel peptide synthesizer 
that can run different sequences, scales and protocols on multiple reactors all at the same time, or 
run up to 12 reaction vessels with preactivation (Figure 16). 
Nevertheless, and although SPPS has evolved a considerable extent, there are still some 
challenges to overcome when synthesizing peptides, including racemization problems, the 
aggregation of peptide chains as the sequence gets longer, the intramolecular interactions that 
make the peptide coil on itself, and other steric hindrance problems. Recently, heat provided by 
microwave radiation (MW) has been used to try to surpass aggregation problems. Since the first 
serious experiments for synthesizing peptides with the help of microwaves in 1992 [105], the Microwave 
Assisted Peptide Synthesis (MAPS) or MW-SPPS approach has evolved greatly and has been 
incorporated in some automated systems, such as the Liberty1 Microwave Peptide Synthesizer© 
developed by CEM Corporation (Figure 17). Additionally, with this approach, coupling reactions are 
much faster and, in many cases, the synthesis yield and the peptides purity are also higher. 
However, some side reactions can be favored as well as the chemical modification of some amino 
acids (cysteine, histidine and aspartic acid are more prone to undergo racemization and other 
modifications). 
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Figure 15: General procedures in SPPS, following the Fmoc/
t
Bu orthogonal protection scheme. 
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Figure 16: Symphony X Multiplex Peptide Synthesizer ©, available in our laboratory. 
 
 
  
Figure 17: CEM Liberty1 Microwave Peptide Synthesizer, used in this project. 
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In summary, the SPPS methodology is faster, simpler, cheaper and more efficient than peptide 
synthesis in solution. Moreover, the current technology and the use of MW radiation make peptide 
synthesis even faster and higher yielding. Nowadays, numerous peptide sequences can be easily 
obtained, containing unnatural amino acids or some structural modification if necessary for their 
application. These modified peptides cannot be provided by the biosynthetic pathway. Thus, SPPS 
has allowed peptides to have a greater prominence and importance in several and diverse areas, 
from biomedical engineering and the development of new drugs to nanotechnology. 
In this project, all peptides were synthesized as C-terminal amides, following standard SPPS 
procedures, with an orthogonal Fmoc/tBu protection scheme. Peptides were synthesized both 
manually and recurring to a CEM Liberty1 Microwave Peptide Synthesizer (Figure 17). 
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2. EXPERIMENTAL 
 
2.1. Reagents, Solvents and Equipments 
All solvents used in this study were of analytical grade. Reagents and solvents were purchased 
from Novabiochem (Fmoc-amino acids and Fmoc-Rink Amide MBHA resin), Merck (TFA and other 
solvents), Sigma-Aldrich (coupling agents, piperidin, N-ethyl-N,N-diisopropylamine (DIPEA) and 3-
(tritylthio)propionic acid) and Carbosynth Ltd. (Berkshire, UK) (gemcitabine hydrochloride). 
Compounds purity and conjugates time-dependent kinetics studies were determined by high-
performance liquid chromatography with diode array detection (HPLC-DAD) on a Merck-Hitachi 
LaChrom Elite equipment, with quaternary pump, automatic and thermostated by Peltier effect 
injector and a diode detector. A reverse phase Purospher star RP C-18 (octadecylsilane) column 
(125 x 4.0 mm), with a particle diameter of 5 !m, was used. The elution was performed with a 
variable gradient of acetonitrile (ACN) in water containing 0.05% trifluoroacetic acid (TFA), at a 1 
mL/min flow and detection at variable wavelength (220 or 270 nm). 
Drug-CPP conjugates were purified by Reverse Phase Medium-Pressure Liquid 
Chromatography (RP-MPLC), using a C18 Vydac® 218TP stationary phase, by Grace Vydac. 
The mass spectrometry analyses were performed on a Thermo Scientific LTQ Orbitrap XL 
spectrometer, with electrospray ionization and both quadrupole ion trap (ESI-IT MS) and Orbitrap 
detection (Materials Centre of the University of Porto, CEMUP). 
After purification and characterization, peptides and conjugates were lyophilized in a BenchTop 
Pro 9L with omnitronics from SP Scientific (Department of Chemistry and Biochemistry of Faculty 
of Sciences of University of Porto). 
Cell viability assays were conducted using flat bottom 96-well plates by TPP Techno Plastic 
Products (Switzerland) and a microplate reader by Bio-tek Instruments Inc. (Powerwave XS, 
Winooski, EUA). 
 
  
FCUP 
Development of New Peptide-Drug Conjugates for Cancer Therapy 
29 
 
EXPERIMENTAL 
2.2. Peptide Synthesis by SPPS 
2.2.1. Manual Synthesis 
2.2.1.1. Experimental setup 
Manual syntheses took place in a polypropylene syringe with a polyethylene porous filter 
adapted to a vacuum system to eliminate the excess of reagents and the solvents used to wash 
the resin after each reaction step. A TeflonTM rod was used to manually stir the resin beads 
throughout the syntheses (Figure 18). 
 
Figure 18: Experimental setup for manual SPPS. 
 
2.2.1.2. Preparation of the resin 
The resin used in the syntheses was the Fmoc-Rink Amide MBHA, a polystyrene-based 
polymer functionalized with 4-methylbenzhydrylamine (MBHA) groups, further modified with an N-
Fmoc protected (R,S)-2-{4-[amino(2,4-dimethoxyphenyl)methyl]phenoxy}acetic acid linker (Rink or 
Knorr linker) (Figure 19). The resin had a 0.60 mmol/g loading capacity and syntheses were 
performed at 0.2 mmol scale, so 0.33 g of resin were required for each synthesis. The dry resin 
was transferred into the syringe and was conditioned in N,N-dimethylformamide (DMF) for 20 min. 
After that time, DMF was rejected and the resin was swelled in dichloromethane (DCM) for another 
15 min. 
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The initial deprotection step (release of the free amino group of the Rink linker) was carried out 
using 20% piperidine in DMF (3 mL, 1 x 1 min + 1 x 20 min). After the deprotection, the resin was 
washed with DMF (3 mL, 3 x 1 min) and DCM (3 mL, 3 x 1 min) and a Kaiser test was performed. 
Upon a positive Kaiser test (dark blue resin beads and solution), release of the free amine groups 
is confirmed and, therefore, the construction of the peptide chain can be initiated. 
 
Figure 19: Chemical structure of the Fmoc-Rink Amide MBHA resin (polystyrene base polymer represented by the grey sphere). 
. 
2.2.1.3. Kaiser Test 
The Kaiser (or ninhydrin) test is a qualitative assay used to detect the presence or absence of 
free primary amino groups, revealing whether a coupling or deprotection step was successful. It is 
based on a colorimetric reaction that occurs between ninhydrin (yellow) and free primary amino 
groups, leading to the formation of a blue chromophore known as Ruhemanns purple (Figure 20). 
Kaiser tests were carried out by transferring a few dry resin beads to a small glass tube and 
adding the test reagents A and B in a 3 to 1 proportion (6 drops of reagent A and 2 drops of 
reagent B). After homogenization, the test tube was placed in an oven at 110 ºC and after 3 
minutes the color of the resin beads and solution was assessed. After coupling one N-Fmoc 
protected amino acid, the peptidyl-resin should not react with ninhydrin, and so it should remain 
yellow (negative test). However, as a successful deprotection step removes the Fmoc group, 
leaving the amine group available to react with ninhydrin, the peptidyl-resin and the solution should 
turn (dark) blue (positive test). When the test indicated a step wasnt completed, that step was 
repeated. 
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Figure 20: Ninhydrin general reaction with primary amines, resulting in the formation of a chromophore. 
 
The preparation of reagents A and B used in the Kaiser tests undertaken was as follows: 
Reagent A: a solution of phenol (40 g) was prepared in 10 mL of ethanol (EtOH). Next, 2 mL of 
an aqueous solution of KCN (16.5 mg/25 mL) were mixed with 100 mL of freshly distilled pyridine. 
Finally, the two solutions were mixed together. 
Reagent B: solution of 5 g of ninhydrin in 100 mL of EtOH (this solution was protected from 
light). 
 
2.2.1.4. Coupling of Amino Acids and Deprotection Cycles  
Prior to coupling, amino acids were activated in solution for approximately 5 min before being 
transferred to the syringe to react with the resin or peptidyl-resin. This activation was accomplished 
by preparing a solution of Fmoc-AA-OH (5 eq.), coupling agent O-(benzotriazol-1-yl)-N,N,N,N-
tetramethyluronium hexafluorophosphate (HBTU, 5 eq.) and base DIPEA (10 eq.) in DMF. 
Solvents are used in only sufficient volumes to ensure the proper solvation of the amino acids and 
the peptidyl-resin beads, which is a crucial condition for efficient chain assembly. The activated 
amino acid solution was then transferred to the reaction vessel to react with the previously 
deprotected resin or peptidyl-resin for 1 h, under stirring. After this time, the peptidyl-resin was 
washed with DMF (3 mL, 3 x 1 min) and DCM (3 mL, 3 x 1 min) to eliminate the excess of 
reagents, solvents and side products and a Kaiser test was performed to confirm the efficiency of 
the coupling. When the Kaiser test was negative, the following deprotection step was carried out, 
using the deprotection solution (20% piperidine in DMF (3 mL, 1 x 1 min + 1 x 20 min). Once 
deprotection was completed, the resin was washed again with DMF (3 mL, 3 x 1 min) and DCM (3 
mL, 3 x 1 min) and another Kaiser test was performed. When the deprotection was confirmed by a 
positive Kaiser test, the next Fmoc-AA-OH was coupled following the same aforementioned 
conditions. The peptide sequence was completed by repeating the cycles of coupling of N-Fmoc 
amino acids and deprotection steps. 
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The procedures for the coupling and deprotection steps are given in detail in Table 1: 
Table 1: General steps of Fmoc/
t
Bu SPPS. 
Step Reagents/Solvents Operation Time (min) Repetitions 
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20% piperidine in DMF (v/v) Deprotection 
1 
20 
1 
1 
DMF Wash 1 3 
DCM Wash 1 3 
Kaiser test Control 3 1 
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Fmoc-AA-OH (5 eq)  
HBTU (5 eq)  
DIPEA (10 eq)  
Coupling 60 1 
DMF Wash 1 3 
DCM Wash 1 3 
Kaiser test Control 3 1 
 
 
2.2.2. SPPS Assisted by Microwave Energy 
A Liberty1 Microwave Peptide Synthesizer (CEM Corporation) was used to synthesize both 
Cys-Penetratin and Cys-pVEC peptides, using a 0.1 mmol scale and Fmoc-Rink Amide MBHA 
resin (loading capacity: 0.60 mmol/g). The resin was conditioned by solvating in DMF for 30 min 
and transferred to the equipments reaction vessel. 
In order to try to obtain better yields, double couplings were programmed for the amino acid 
residues tryptophan, glutamine, serine and arginine, as well as for the first amino acid of each 
sequence (lysine for both peptides). The experimental conditions for the coupling and deprotection 
steps are detailed in Table 2. 
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Table 2: Experimental conditions for SPPS on the CEM Libery1 Peptide Synthesizer. 
Step Reagents/Solvents 
Microwave 
Power (W) 
Temperature 
(ºC) 
Time (s) 
Removal of Fmoc 
group from the resin 
Deprotection solution 
35 75 30 x 2 
Removal of Fmoc 
group from the AA 
35 75 180 
Fmoc-AA-OH coupling 
Fmoc-AA-OH (0.2 M in DMF) 
Activator solution 
Activator base solution 
30a 75a 300a 
a
 25 W, 50 ºC and 240 s for Fmoc-Cys(Trt)OH;  25 W, 75 ºC and 300 s for Fmoc-Arg(Pbf)-OH. 
 
In the MW-assisted synthesis of the target peptides, the composition of the deprotection, 
coupling activator and coupling base solutions were as follows: 
Deprotection solution: 20% piperidine (v/v), HOBt·H2O 0.1 M in DMF 
Activator solution: HBTU, HOBt 0.5 M in DMF 
Activator base solution: DIEA 2.0 M in NMP 
 
2.3. Cleavage: separating the peptide from the resin and 
removing the side chain protecting groups 
When the peptidic sequence was completed and after the final deprotection, the peptidyl-resin 
was subjected to a chemical treatment that cleaves the bond linking the peptide to the resin beads. 
First, a cleavage cocktail (cocktail R) was prepared in the hood, containing 90% TFA, 5% 
thioanisole, 3% 1,2-ethanedithiol and 2% anisole (v/v). Then, the dry peptidyl-resin was transferred 
to 15 mL Falcon tubes in 100 mg portions and 1 mL of cleavage cocktail was added to each 
portion. The tubes were left under orbital stirring for 2.5 h at room temperature. After that time, the 
peptide should be soluble in the solution and so the content of the tubes was filtered on a D4 
funnel previously rinsed with TFA, and the resin beads were washed with TFA. The filtrate, 
containing the soluble peptide, was transferred to new Falcon tubes in 1 mL portions and 14 mL of 
cold tert-butyl methyl ether were added to each tube. After slightly shaking the tubes, they were 
cooled to -22 ºC for about 8 minutes and then centrifuged at 3500 rpm for 7 minutes at -5 ºC. The 
ether was carefully rejected and fresh ether was added again. The addition of ether and 
centrifugation were repeated 3 more times and finally the tubes were left in a vacuum desiccator 
until the crude peptide was dry. Dry peptide pellets were then solubilized in 10% aqueous acetic 
acid and analyzed by HPLC-DAD and HPLC hyphenated with ESI-IT MS (LC-MS). 
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2.4. Structural modification of Gemcitabine 
In order to conjugate gemcitabine with the CPPs, the hydrochloride salt of the drug was 
chemically modified to compound (4) according to a recently described protocol [67]. Firstly, 
gemcitabine had to be modified to N-[3-(S-trityl)sulfanyl]propanoylgemcitabine (3), after which the 
trityl (Trt) protecting group was removed, producing the free thiol, i.e. yielding N-(3-
sulfanyl)propanoylgemcitabine (4) (Figure 21). Compound (4) was then used for either the direct 
coupling with the Cys-modified CPPs (route e) in Figure 21) (Strategy A) or for subsequent S-
derivatization with 2,2-disulfanyldipyridine to afford compound (7), that was next coupled to the 
Cys-modified CPPs (route d) in Figure 21) to produce the target conjugates (5) (Strategy B). 
Detailed procedures are next described. 
 
Figure 21: Synthesis of new CPP-Gemcitabine conjugates (5). a) 3-(S-trityl)sulfanylpropanoic acid (2), TBTU, DIEA, DMF, 0 ºC - rt, 
24h, (45%); b) DCM/TFA 1:1, Et3SiH 0 ºC, 1h (95%); c) 2,2-disulfanyldipyridine (6), MeOH, AcOH, rt, 24h (60%); d) DMF, rt, 24 h (95% 
for Pen; 60% for pVEC); e) 5% DMSO in H2O/ACN (3:1), pH 8 (dil. NH4OH), 24h.  
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2.4.1. Synthesis of N-[3-(S-trityl)sulfanyl]propanoylgemcitabine  (3) 
Briefly, 3-(S-trityl)sulfanylpropanoic (0.24 g, 0.6 mmol) was dissolved in 2 mL of anhydrous 
DMF. The reaction mixture was brought to 0 ºC and then O-(Benzotriazol-1-yl)-N,N,N,N-
tetramethyluronium tetrafluoro borate (TBTU) (0.26 g, 0.8 mmol) was added to this solution 
followed by 0.2 mL (1.3 mmol) of DIPEA. After 30 min, gemcitabine hydrochloride (0.2 g, 0.7 mmol) 
was added to the reaction mixture, which was stirred for another 30 min at 0 ºC and then allowed 
to warm to room temperature and stirred for 24 h, and monitored by TLC. The reaction mixture was 
washed with DCM 3 times and the solvents were evaporated under reduced pressure. Liquid
liquid extraction followed by liquid chromatography on silica-gel using DCM/propanone (Me2CO) 
1:1 (v/v) as eluent were performed to purify the crude product. Compound (3) was obtained with a 
45% yield. 
 
2.4.2. Synthesis of N-(3-sulfanyl)propanoylgemcitabine  (4) 
Compound (3) (0.4813 g, 1 eq) was brought to 0 ºC and 2.0 mL of a TFA:DCM (1:1 v/v) solution 
were added followed by triethylsilane (TES) (2.4 eq). The mixture was stirred for 2 h, and the 
solvents were then removed under reduced pressure. The crude product was washed with tert-
butyl methyl ether 3 times and dried under reduced pressure. Compound (4) was obtained with a 
95% yield and analyzed by HPLC at 2 different wavelengths and by ESI-IT MS. 
 
2.5. First approach to the synthesis of the conjugate 
Gemcitabine LinkerPenetratin: Strategy A 
To obtain the desired conjugates, a protocol described by Albericio et al. for the formation of a 
disulfide bridge between the modified drug and the Cys-modified peptide was followed [106]. To 
that purpose, compound (4) and the peptide Cys-Penetratin were dissolved in H2O/ACN (3:1 v/v, 4 
mL) containing 5% dimethylsulfoxide (DMSO), and the pH was adjusted to 8.0 with dilute NH4OH. 
The reaction mixture was stirred at room temperature and monitored by HPLC (elution in gradient 
mode, 0  100% ACN in water with 0.05% TFA). After 26 h of reaction, the solvents were removed 
under reduced pressure and the crude product was washed with methanol (MeOH). Once the 
product was dried in a vacuum desiccator, it was analyzed by HPLC at 2 different wavelengths and 
LC-ESI/MS and found not to correspond to the target conjugate. 
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2.6. Synthesis of the GemcitabineLinkerCPP conjugates: 
Strategy B 
 
Figure 22: Synthesis of Gemcitabine-dithiopyridine (7). 
 
N-(3-sulfanyl)propanoylgemcitabine (4) was converted into  N-{3-[S-(2-sulfanyl)pyridyl]sulfanyl} 
propanoylgemcitabine (7) following a protocol described by Dasari et al. [67]. Briefly, compound (4) 
(0.038 g, 0.1 mmol) and 2,2-disulfanyldipyridine (6) (0.054 g, 0.25 mmol) were dissolved in 
anhydrous MeOH (2.5 mL) containing glacial acetic acid (1.8 µL, 0.03 mmol). The reaction mixture 
was stirred at room temperature for 24 h and monitored by TLC. The crude product was purified by 
column chromatography on silica-gel, using DCM/MeOH 7:1 as eluent (60% yield), and its 
structure subsequently identified as compound (7) by HPLC and ESI-IT MS. 
To obtain the conjugates, compound (7) (0.022 g, 0.047 mmol) and CysCPPs (0.056 g, 0.024 
mmol) were dissolved in anhydrous DMF with triethylamine (3.3 µL, 0.024 mmol). The reaction 
mixture was stirred under an argon atmosphere and monitored by HPLC. After 24 h, the reaction 
was stopped and the crude product was analyzed by HPLC and LC/ESI-MS (95% yield for 
conjugation with Cys-Pen and 60% for Cys-pVEC). 
  
2.7. Purification of the conjugates 
 Drug-peptide conjugates were solubilized in the minimum volume required of 10% aqueous 
acetic acid and purified by Reverse Phase Medium-Pressure Liquid Chromatography (RP-MPLC), 
using ACN in water with 0.05% TFA as eluent, in gradient mode (15  40%). The collected 
fractions were analyzed by HPLC to determine which contained the conjugate with a purity greater 
than 92%. These fractions were subsequently pooled and lyophilized. 
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2.8. Stability studies 
2.8.1. Calibration curve 
A phosphate-buffered saline (PBS) with pH = 7.4 was prepared and seven gemcitabine 
standard solutions with different concentrations (100.0, 85.0, 70.0, 55.0, 40.0, 20.0, and 10.0 
µg/mL) were prepared in that buffer to trace the calibration curve. These solutions and the PBS 
control ([Gemcitabine] = 0 µg/mL) were analyzed by HPLC, using ACN in water with 0.05% TFA as 
eluent, in gradient mode (0  100%), for 30 minutes, at a flow rate of 1 mL/min and detection at ! = 
220 and 270 nm. The calibration curve was traced using the absorption values of the peak relative 
to gemcitabine. 
 
2.8.2. Study of conjugates stability at physiological pH and temperature 
To determine the extension of the hydrolysis of the conjugates bonds, both Gemcitabine
LinkerPenetratin and GemcitabineLinkerpVEC conjugates were dissolved in PBS (200.0 
µg/mL) and left under magnetic agitation for 6 days at 37 ºC, with periodic uptake of aliquots that 
were subjected to HPLC analysis, with detection at 220 and 270 nm. 
This study was repeated for the GemcitabineLinkerPenetratin conjugate, in the same 
conditions, for 22 days. 
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2.9. In vitro growth inhibition assays 
2.9.1. Cell cultures 
2.9.1.1. Cell cultures conditions 
All the manipulations involving cell cultures were performed in a vertical laminar flow cabinet 
biosafety level 2A (ADS Laminaire). Cell cultures were always incubated at a temperature of 37 ºC 
in a humidified atmosphere with 5% CO2. 
 
2.9.1.2. Cell lines 
Three different cell lines were tested in this study: Caco-2 (heterogeneous human epithelial 
colorectal adenocarcinoma), MKN-28 (human gastric cancer) and HT-29 (human colon 
adenocarcinoma). The cells were grown as monolayer in cell culture plates and maintained in cell 
culture medium. Cells were always exponentially growing, having conducted its subculture by 
trypsinization, once or twice a week. 
Caco-2 and HT-29 cells were kindly provided from Faculty of Medicine of University of Porto 
(FMUP) and MKN-28 cells were provided by the Institute of Molecular Pathology and Immunology 
of the University of Porto (IPATIMUP, Porto, Portugal). 
 
2.9.1.3. Culture medium 
Caco-2 cells were maintained in Minimum Essential Medium (MEME), supplemented with 15% 
of inactivated fetal bovine serum (FBS), 2 mL of glutamax (L-alanyl-L-glutamine), 1% 
antibiotic/antimycotic solution (100 units/mL penicillin, 100 "g/mL streptomycin and 2.5 "g/mL of 
amphotericin B). To inactivate FBS, the serum was in a water bath at 56 ºC for 1 h. 
MKN-28 and HT-29 cells were maintained in complete culture medium RPMI 1640 AQmedia 
containing 10% heat-inactivated FBS, 1% antibiotic/antimycotic solution (100 units/mL penicillin, 
100 "g/mL streptomycin and 2.5 "g/mL of amphotericin B). 
 
2.9.1.4. Trypsinization of the cell lines 
The trypsinization consisted on the detachment of the monolayer cells upon the action of a 
trypsin solution. Briefly, after removing the cell culture medium, the cells were washed with PBS 
and the trypsin solution was added. After 1 min, the excess of trypsin was removed and the cells 
were then incubated for about 5 min at 37 ºC, until the cells are detached from the culture plate. 
Trypsin action was terminated by the addition of culture medium, through the inhibitors present in 
FBS. 
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2.9.1.5. Evaluation of cell viability 
Cell viability was evaluated with the vital stain, trypan blue. After trypsinization, the total number 
of viable cells was determined for all cell lines. For this purpose, 50 µL of cell suspension were 
added to 50 µL of trypan blue and the number of viable cells (not colored, because of their ability to 
exclude the stain) was determined in a Neubauer chamber. The number of viable cells was 
expressed per mL of cellular suspension. 
 
2.9.1.6. Maintaining cells in exponentially growth phase 
After trypsinization, cell density was adjusted to 1.5 x 105 viable cells/mL, in culture medium. 
 
2.9.2. Sulforhodamine B (SRB) assay: evaluation of the antiproliferative 
activity of the compounds 
The effect of the compounds on the growth of the three cell lines was evaluated according to 
the procedure adopted by the National Cancer Institute (NCI, USA) in the In vitro Anticancer Drug 
Discovery Screen that uses the protein-binding dye Sulforhodamine B (SRB) to assess cell growth 
[107, 108]. This is a micromethod that uses 96-well plates and evaluates the effect of compounds 
on exponentially growing cells after continuous exposure for 48 h, through the quantification of the 
cellular protein content by the protein dye SRB. 
The cell lines were inoculated in flat bottom 96-well plates (100 µL/well) at the density that 
ensures the exponential grow, and incubated for 24 h before the addition of the compounds, to 
allow the cells to adhere and stabilize. Five different concentrations were tested for each 
compound: 100.0; 50.0; 25.0; 12.5 e 6.3 µM (100 µL/well), which were prepared by serial dilution 
(1:2) in culture medium. In the control cells, the addition of compound was replaced by the addition 
of culture medium. 
After a 48 h incubation with the compounds, the cells were fixated with a solution of 
trichloroacetic acid (TCA) 50% for 60 min at 4 ºC, followed by a wash step with H2O. The plates 
were completely dried, and the cells were then dyed with a SRB solution (0.4% in 1% acetic glacial 
acid) (50 mL/well) for 30 min, at room temperature. The excess of SRB was removed and the 
plates were washed with a solution of 1% acetic acid. Plates were dried once again and the bound 
SRB was solubilized in Tris-HCl buffer (10 mM in H2O, pH 10.5) (100 µL/well). The absorbance 
was measured at 492 nm in a microplate reader. Cellular proliferation was expressed as the 
percentage of optic density (OD) relative to the OD of the control cells. 
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3. RESULTS AND DISCUSSION 
 
3.1. Peptide Synthesis 
3.1.1. Manual Synthesis of Cys-Penetratin 
After the manual synthesis of the peptide Penetratin, modified with an N-terminal cysteine 
residue (Cys-Pen) to allow the posterior conjugation to modified gemcitabine, the peptide was 
cleaved from the resin following the protocol described in the Experimental section. Once dried in 
the vacuum desiccator and then solubilized in 10% aqueous acetic acid, the crude product was 
analyzed by HPLC and LC-ESI/MS (Figure 23 and Figure 24). The sequence and exact mass of 
the Cys-Pen and the m/z ratios of its adducts with H+ detected by ESI-IT MS are presented in 
Table 3. 
 
Table 3: Sequence and exact mass of the Cys-Penetratin peptide and m/z ratios of its adducts with H
+
 detected by ESI-IT MS. 
Peptide Sequence Exact Mass (Da) 
Cys-Penetratin C-RQIKIWFQNRRMKWKK 2347.3147 
   
Adducts m/z 
(P + 2H)2+ 1175.4606 
(P + 3H)3+ 783.9737 
(P + 4H)4+ 588.2303 
(P + 5H)5+ 470.7842 
(P + 6H)6+ 392.4869 
(P + 7H)7+ 336.5602 
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Figure 23: Chromatogram of the crude product obtained in the manual synthesis of Cys-Penetratin, acquired with a HPLC-DAD 
system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 30 minutes, at a flow rate of 
1 mL/min and detection at ! = 220 nm. The arrow indicates the chromatographic peak that was identified as the target peptide by LC-
ESI/Orbitrap MS (mass spectrum on Figure 24). 
 
 
Figure 24: Mass spectrum (LC-ESI/Orbitrap MS, positive mode) of the Cys-Penetratin peptide (manual synthesis). 
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RESULTS AND DISCUSSION 
Together, these results show that the manual synthesis of this peptide results in a very complex 
combination of different products. The HPLC chromatogram shows the formation of various 
compounds and the MS reveals that the intended peptide (rt = 10.4 min), detected as different 
protonated and TFA adducts, was a minor product of the synthesis whose isolation was not viable. 
The manual synthesis of this peptide was repeated, but similar results (not shown) were 
obtained. 
 
3.1.2. Manual Synthesis of Cys-pVEC 
The peptide pVEC was also synthesized manually, bearing the same N-terminal modification 
(insertion of a cysteine residue) for subsequent coupling to modified gemcitabine. After cleaving 
and drying the crude product, it was analyzed by HPLC (chromatogram presented in Figure 25). 
Similarly to the previous synthesis of the Cys-Penetratin peptide, the manual synthesis of the Cys-
pVEC peptide (C-LLIILRRRIRKQAHAHSK) resulted in a very complex crude product, as verified in 
the HPLC chromatogram. Again, it was not viable to isolate this peptide from crude product, and its 
further characterization by LC-ESI/MS was considered unnecessary. 
 
Figure 25: Chromatogram of the product of the manual synthesis of the peptide Cys-pVEC, acquired with a HPLC-DAD system, with 
a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 30 minutes, at a flow of 1 mL/min and 
detection at ! = 220 nm. 
 
In the view of the fact that the manual synthesis of these peptides was not successful, it was 
decided to carry out their synthesis by resorting to the CEM Liberty1 peptide synthesizer, with 
microwave radiation, available in the laboratory, as next described.  
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RESULTS AND DISCUSSION 
3.1.3. Automated MW-assisted Synthesis of Cys-Penetratin 
The peptide Cys-Penetratin was synthesized in the CEM Liberty1 peptide synthesizer, assisted 
with microwave radiation. The peptide was cleaved from the solid support, and after the work-up 
described in the Experimental Section, it was solubilized in 10% aqueous acetic acid and analyzed 
by HPLC and LC-ESI/MS. The chromatogram and mass spectrum obtained are presented in 
Figure 26 and Figure 27, respectively. 
 
Figure 26: Chromatogram of the product of the synthesis of the peptide Cys-Penetratin in the CEM Liberty1 MW-assisted 
synthesizer, acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0 
 100%), for 30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
 
 
Figure 27: Mass spectrum (LC-ESI/MS Orbitrap, positive mode) of the Cys-Penetratin peptide (MW-assisted synthesis). 
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RESULTS AND DISCUSSION 
HPLC analysis revealed that the automated synthesis of the Cys-Pen peptide results in a much 
simpler crude product, with a distinct main compound (rt = 11 min), whose LC-ESI/MS analysis 
confirmed as the target peptide, which has an exact mass of 2347.3147 Da. In fact, several peaks 
can be observed in the mass spectrum of the crude product, corresponding to different protonation 
states of the Cys-Pen peptide. 
 
3.1.4. Automatic MW-assisted Synthesis of Cys-pVEC 
The peptide Cys-pVEC was also synthesized in the CEM Liberty1 synthesizer and analyzed by 
HPLC and LC-ESI/MS after cleavage from the solid support and subsequent work-up (Figure 28 
and Figure 29). The sequence and exact mass of the Cys-pVEC peptide and the m/z ratios of its 
adducts with H+ detected by ESI-IT MS are presented in Table 4. 
 
Figure 28: Chromatogram of the product of the synthesis of the peptide Cys-pVEC in the CEM Liberty1 MW-assisted synthesizer, 
acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 
30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
 
The HPLC chromatogram confirmed the formation of a main product, with rt = 11.2 min, which 
was identified as the target Cys-pVEC peptide by LC-ESI/MS analysis. It is possible to observe 
several peaks in the mass spectrum, corresponding to different protonation states of the peptide. 
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RESULTS AND DISCUSSION 
 
Figure 29: Mass spectrum (LC-ESI/MS Orbitrap, positive mode) of the Cys-pVEC peptide (MW-assisted synthesis). 
 
Table 4. Sequence and exact mass of the Cys-pVEC peptide and m/z ratios of its adducts with H
+
 detected by ESI-IT MS. 
Peptide Sequence Exact Mass (Da) 
Cys-pVEC C- LLIILRRRIRKQAHAHSK 2311.4012 
 
Adducts m/z 
(P + 2H)2+ 1156.9401 
(P + 3H)3+ 771.6267 
(P + 4H)4+ 578.9700 
(P + 5H)5+ 463.3760 
(P + 6H)6+ 386.3134 
(P + 7H)7+ 331.2686 
 
The success of both syntheses using the CEM Liberty1 synthesizer demonstrates the 
importance of the microwave radiation to synthesize these peptides. This approach afforded both 
peptides with excellent purity grades, dismissing the need to purify them. The heat provided by the 
MW decreases the coiling of the peptide chain on itself as it grows and the aggregation between 
chains (caused by intramolecular and intermolecular interactions, respectively) at the same time as 
it reduces the time required for the condensation and deprotection reactions to occur. 
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RESULTS AND DISCUSSION 
3.2. Structural modification of Gemcitabine 
After synthesizing the target CPPs, modified with an N-terminal cysteine residue, gemcitabine 
was also chemically modified, as described in the Experimental section, to enable its conjugation 
to the Cys-CPPs through a disulfide bond. To this end, the synthetic route displayed in Figure 21 
was followed, pursuing synthesis of N-[3-(S-trityl)sulfanyl]propanoylgemcitabine (3), N-(3-
sulfanyl)propanoylgemcitabine (4) and N-{3-[S-(2-sulfanyl)pyridyl]sulfanyl}propanoylgemcitabine 
(7), the latter being next coupled to the Cys-modified CPPs to produce the target CPP-gemcitabine 
conjugates. Results from the syntheses of compounds (3), (4) and (7) are next described. 
 
 
3.2.1. Synthesis of N-[3-(S-trityl)sulfanyl]propanoylgemcitabine (3) 
The synthesis of compound (3) was carried out as described in the Experimental Section, and 
an ESI-IT MS analysis of the isolated product was performed. The mass spectrum obtained is 
represented in Figure 30, and confirms the expected structure for compound (3), which was 
obtained with 45% yield. 
 
 
Figure 30: Mass spectrum (LC-ESI/MS Orbitrap, positive mode) of compound (3). 
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RESULTS AND DISCUSSION 
3.2.2. Synthesis of N-(3-sulfanyl)propanoylgemcitabine (4) 
The synthesis of compound (4) was carried out as described in the Experimental Section. The 
isolated product was analyzed by HPLC-DAD and by ESI-IT MS. The resulting chromatogram and 
mass spectrum are represented in Figure 31 and Figure 32, respectively. While the HPLC 
chromatogram revealed the formation of a major product, with a retention time of 14.2 min, ESI-IT 
MS analysis confirmed this product to have the molecular mass expected for compound (4), whose 
molecular weight is 351.3248 g/mol. Still, some traces of unreacted gemcitabine were also 
detected in the mass spectrometry analysis (gemcitabine molecular weight is 263.20 g/mol). 
 
 
Figure 31: Chromatogram of compound (4), acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% 
TFA as eluent, in gradient mode (0  100%), for 30 minutes, at a flow of 1 mL/min and detection at ! = 270 nm. 
 
In face of successful synthesis of (4), and of the relatively low amount of impurities of the 
product isolated, this was subsequently used without further purification for direct conjugation with 
the Cys-Pen peptide (see 3.3.1). 
 
Minutes
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
m
A
U
-200
0
200
400
600
800
1000
1200
1400
1600
1800
2000
m
A
U
-200
0
200
400
600
800
1000
1200
1400
1600
1800
2000
DAD-CH2  268 nm
Composto 2
FCUP 
Development of New Peptide-Drug Conjugates for Cancer Therapy 
48 
 
RESULTS AND DISCUSSION 
 
Figure 32: Mass spectrum (LC-ESI/MS Orbitrap, positive mode) of compound (4). 
 
 
3.2.3. Synthesis of N-{3-[S-(2-sulfanyl)pyridyl]sulfanyl}propanoyl-
gemcitabine (7) 
Compound (7) was produced by reacting N-(3-sulfanyl)propanoylgemcitabine (4) with 2,2-
disulfanyldipyridine, as described in the Experimental Section. The isolated product was analyzed 
by HPLC and by ESI-IT MS, yielding the chromatogram and mass spectrum presented in Figure 33 
and Figure 34, respectively. Results obtained confirmed that compound (7), whose molecular 
weight is 460.4708 g/mol, was the main product of this synthesis (rt observed in the HPLC = 13.1 
min). Compound (7) was next used for conjugation with both Cys-Pen and Cys-pVEC peptides 
(see 3.2.2. and 3.3.3.). 
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RESULTS AND DISCUSSION 
 
Figure 33: Chromatogram of compound (7), acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% 
TFA as eluent, in gradient mode (0  100%), for 30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
 
 
 
Figure 34: Mass spectrum (ESI-IT MS Orbitrap, positive mode) of compound (7). 
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RESULTS AND DISCUSSION 
3.3. Synthesis of the Drug-CPP Conjugates 
3.3.1. Strategy A  direct conjugation of compound (4) with Cys-Penetratin 
Conjugation of compound (4) with the Cys-Pen peptide was attempted as described in the 
Experimental section. The course of the reaction was monitored by HPLC at two different 
wavelengths (220 and 270 nm) and the final product was analyzed by both HPLC and LC-ESI/MS. 
HPLC monitoring of reaction progress revealed that some kind of complex process was taking 
place, instead of a clean conversion of starting material(s) into the expected single product (data 
not shown). Figure 35 depicts the HPLC chromatogram of the starting Cys-Pen peptide, whereas 
Figure 36 and Figure 37 reproduce the chromatograms of the final reaction mixture with detection 
at 220 and 270 nm, respectively. The apparent formation of a major product was detected in the 
HPLC analysis with detection at 220 nm, by observation of a peak with a retention time of 13.1 min 
(Figure 36). In turn, HPLC analysis with detection at 270 nm revealed some release of gemcitabine 
(rt = 6.8 min) from degradation of the starting compound (4). 
 
Figure 35: Chromatogram of the Cys-Penetratin peptide, acquired with a HPLC-DAD system, with a C18 column, using ACN in 
water with 0.05% TFA as eluent, in gradient mode (15  40%), for 30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
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RESULTS AND DISCUSSION 
 
Figure 36: Chromatogram of the reaction mixture obtained in the attempt of producing the target GemcitabineLinkerPenetratin 
conjugate, following strategy A; data acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as 
eluent, in gradient mode (15  40%), for 30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
 
 
Figure 37: Chromatogram of the reaction mixture obtained in the attempt of producing the target GemcitabineLinkerPenetratin 
conjugate, following strategy A; data acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as 
eluent, in gradient mode (15  40%), for 30 minutes, at a flow of 1 mL/min and detection at ! = 270 nm. 
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RESULTS AND DISCUSSION 
The mass spectrum from the LC-ESI/MS analysis of the mixture is presented in Figure 38, and 
shows that none of the ions observed correspond to the exact mass of the target conjugate (Figure 
43), or of any of its protonated adducts (whose m/z ratios are presented in Table 5).  
Release of parent gemcitabine from its derivative (4) was also confirmed by LC-ESI/MS analysis 
(not shown). 
 
Figure 38: Mass spectrum (LC-ESI/MS Orbitrap, positive mode) relative to the most intense peak of the HPLC, highlighting three 
adducts of the Cys-Penetratin peptide. 
 
Table 5: Exact mass of the GemcitabineLinkerPenetratin conjugate and m/z ratios of its adducts with H
+
. 
Conjugate  Exact Mass (Da) 
GemcitabineLinkerPenetratin 2696.3691 
  
Adducts m/z 
(C + 2H)2+ 1349.1846 
(C + 3H)3+ 899.7897 
(C + 4H)4+ 675.0923 
(C + 5H)5+ 540.2738 
(C + 6H)6+ 450.3949 
(C + 7H)7+ 386.1956 
(C + 8H)8+ 338.0461 
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RESULTS AND DISCUSSION 
3.3.2. Strategy B  conjugation of compound (7) with Cys-Penetratin 
Compound (7) and the Cys-Penetratin peptide were conjugated as described in the 
Experimental section, and the reaction progress monitored by HPLC (not shown), taking the 
chromatogram of the starting Cys-Pen peptide (Figure 39) as reference. The final product was 
analyzed by HPLC and LC-ESI/MS, with results depicted in Figure 40 and Figure 41, respectively. 
 
Figure 39: Chromatogram of the Cys-Penetratin peptide, acquired with a HPLC-DAD system, with a C18 column, using ACN in 
water with 0.05% TFA as eluent, in gradient mode (0  100%), for 30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
 
Figure 40: Chromatogram of the crude GemcitabineLinkerPenetratin conjugate, acquired with a HPLC-DAD system, with a C18 
column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 30 minutes, at a flow of 1 mL/min and detection 
at ! = 220 nm. 
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RESULTS AND DISCUSSION 
 
Figure 41: Mass spectrum (LC-ESI/MS Orbitrap, positive mode) of the GemcitabineLinkerPenetratin conjugate. 
The chromatogram depicted on Figure 40 shows that the main product of this synthesis has a 
retention time of 11.1 min, whereas the mass spectrum on Figure 41 display several ions whose 
m/z values match those expected for different protonation states of the target conjugate (Table 5). 
It was also possible to detect unreacted compound (7) (which has a retention time of 13.3 min in 
the HPLC), both as a monomer (m/z = 461.08) and as a dimer. 
The GemcitabineLinkerPenetratin conjugate was purified by RP-MPLC, using ACN in water 
with 0.05% TFA as eluent, in gradient mode (15  40%) and was obtained 100% pure (Figure 42). 
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RESULTS AND DISCUSSION 
 
Figure 42: Chromatogram of the GemcitabineLinkerPenetratin conjugate after purification, acquired with a HPLC-DAD system, 
with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 30 minutes, at a flow of 1 mL/min 
and detection at ! = 220 nm. 
 
 
Figure 43: Chemical structure of the Gemcitabine  Linker  Penetratin conjugate (exact mass 2696.3691 Da). 
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RESULTS AND DISCUSSION 
3.3.3. Strategy B  conjugation of compound (7) with Cys-pVEC 
Since conjugation strategy B successfully produced the target GemcitabineLinkerPenetratin 
conjugate, the same protocol was applied to the synthesis of the GemcitabineLinkerpVEC 
conjugate. As before, the reaction progress was monitored by HPLC (not shown), taking the 
chromatogram of the Cys-pVEC peptide (Figure 44) as reference. The final conjugate was 
analyzed by HPLC and LC-ESI/MS, with results as depicted in Figure 45 and Figure 46, 
respectively. 
 
Figure 44: Chromatogram of the Cys-pVEC peptide, acquired with a HPLC-DAD system, with a C18 column, using ACN in water 
with 0.05% TFA as eluent, in gradient mode (0  100%), for 30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
 
Figure 45: Chromatogram of the GemcitabineLinkerpVEC conjugate, acquired with a HPLC-DAD system, with a C18 column, 
using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 30 minutes, at a flow of 1 mL/min and detection at ! = 
220 nm. 
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RESULTS AND DISCUSSION 
 
Figure 46: Mass spectrum (LC-ESI/MS Orbitrap, positive mode) of the GemcitabineLinkerpVEC conjugate. 
 
Once again, it was possible to confirm that the target GemcitabineLinkerpVEC conjugate 
(Figure 47) was successfully synthesized, though the crude product was not as pure as that 
obtained in the synthesis of the Gemcitabine-Penetratin conjugate. The GemcitabineLinkerpVEC 
conjugate presented a retention time of 11.3 min (Figure 45) and the ions displayed in its mass 
spectrum (Figure 46) presented m/z values that matched those of its different protonation adducts 
(Table 6). Again, unreacted compound (7) could be detected by ESI-IT MS (m/z = 461.08) (HPLC 
retention time of 13.8 min). 
 
Figure 47: Chemical structure of the Gemcitabine  Linker  pVEC conjugate. 
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RESULTS AND DISCUSSION 
 
Table 6: Exact mass of the GemcitabineLinkerpVEC conjugate and m/z ratios of its adducts with H
+
. 
Conjugate  Exact Mass (Da) 
GemcitabineLinkerpVEC 2660.4556 
  
Adducts m/z 
C + 2H+ 1331.2278 
C + 3H+ 887.8185 
C + 4H+ 666.1139 
C + 5H+ 533.0911 
C + 6H+ 444.4093 
C + 7H+ 381.0651 
 
This conjugate was purified by RP-MPLC, using ACN in water with 0.05% TFA as eluent, in 
gradient mode (15  40%) and was obtained with 94% purity (Figure 48). 
 
Figure 48: Chromatogram of the GemcitabineLinkerpVEC conjugate after purification, acquired with a HPLC-DAD system, with a 
C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 30 minutes, at a flow of 1 mL/min and 
detection at ! = 220 nm. 
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RESULTS AND DISCUSSION 
3.4. Studies on the stability of Drug-CPP conjugates 
In order to determine how stable were the conjugates hydrolysable bonds (Figure 49), at 
physiological pH and temperature, the stability of both GemcitabineLinkerPenetratin and 
GemcitabineLinkerpVEC conjugates was tested in PBS, pH 7.4, at 37 ºC for 6 days. HPLC 
analyses, with detection at 220 and 270 nm, were performed periodically to detect both the release 
of free gemcitabine and the hydrolysis of the conjugates. To this end, a calibration curve of 
gemcitabine was built prior to hydrolysis studies. Relevant graphs and chromatograms are 
presented further below. 
 
Figure 49: Schematic representation of the Peptide-Drug conjugates, highlighting the hydrolysable bonds. 
 
3.4.1. Calibration curve 
A calibration curve of gemcitabine was initially traced to determine if the correlation between the 
concentration of gemcitabine and the area under its chromatographic peak, detected at 270 nm, 
was linear. The linear correlation was confirmed as demonstrated by the graphic depicted in Figure 
50. 
 
Figure 50: Calibration curve by HPLC analysis of gemcitabine solutions with different concentrations, with detection at ! = 270 nm. 
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RESULTS AND DISCUSSION 
3.4.2. Time-dependent kinetics of the conjugates hydrolysis   
After 6 days in PBS, pH 7.4, 37 ºC, chromatographic analyses reveals that the conjugates suffer 
minimal degradation, and have different kinetic profiles, as shown by the [Gemcitabine] = f(time) 
and [Conjugate] = f(time) graphical representations (Figure 51 and Figure 52; HPLC 
chromatograms performed periodically are included in the Supplementary Information section). 
The GemcitabineLinkerpVEC conjugate produces a significant and exponential release of 
free gemcitabine, making most of the previously conjugated drug available within the first 48 h. On 
the other hand, the GemcitabineLinkerPenetratin conjugate releases gemcitabine more slowly 
and linearly over time, demonstrating a different behavior when it comes to the hydrolysis of the 
conjugates bonds, based only on peptide sequence. 
 
After analyzing these results, the time-dependent kinetics of the hydrolysis of the Gemcitabine
LinkerPenetratin conjugate was studied for 22 days, in the same conditions. 
 
 
Figure 51: Graphical representation of the time-dependent release kinetics of free gemcitabine from the hydrolysis of Gemcitabine
LinkerPenetratin and GemcitabineLinkerpVEC conjugates in PBS (pH 7.4) at 37 ºC (! = 270 nm). 
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Figure 52: Graphical representation of the time-dependent kinetics of GemcitabineLinkerPenetratin and GemcitabineLinker
pVEC conjugates hydrolysis in PBS (pH 7.4) at 37 ºC (! = 220 nm). 
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RESULTS AND DISCUSSION 
3.4.3. Time-dependent kinetics of the GemcitabineLinkerPenetratin 
conjugate (over 22 days) 
 
After 22 days, the degradation of the GemcitabineLinkerPenetratin conjugate is evident. 
However, the release of free gemcitabine from hydrolysis of this conjugate still doesnt present an 
adequate profile for drug release under the tested conditions, considering its higher chemical 
stability over a long period of time (Figure 53 and Figure 54). 
 
Figure 53: Graphical representation of the 22 days study on the time-dependent release kinetics of free gemcitabine from the 
hydrolysis of GemcitabineLinkerPenetratin conjugate in PBS (pH 7.4) at 37 ºC (! = 270 nm). 
 
 
Figure 54: Graphical representation of the 22 days study on the time-dependent kinetics of GemcitabineLinkerPenetratin 
conjugates hydrolysis in PBS (pH 7.4) at 37 ºC (! = 220 nm). 
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RESULTS AND DISCUSSION 
3.5. Antiproliferative activity of the conjugates  SRB assay 
After synthesizing the conjugates and determining their stability under physiological conditions, 
a preliminary study to evaluate the conjugates antiproliferative activity was performed against 
three different cell lines: MKN-28 (human gastric cancer), Caco-2 (heterogeneous human epithelial 
colorectal adenocarcinoma) and HT-29 (human colon adenocarcinoma). Cells treated only with 
gemcitabine served as the control of this experiment. The GemcitabineLinkerpVEC conjugate 
was not tested against HT-29 cells because there was not a sufficient mass of this conjugate. 
Results are shown in Figure 55 and Table 7. 
 
 
 
Table 7: Summary of the results of the antiproliferative activity of the compounds, with indication of the IC50 (µM). 
 
IC50 (µM) (Mean ± SEM) 
Compound MKN-28 (stomach) Caco-2 (colon) HT-29 (colon) 
Drug > 100 > 100 32.23 ± 10.45 
Drug-Pen 48.11 ± 9.30 67.04 ± 4.15 38.78 ± 21.09 
Drug-pVEc > 100 > 100  -  
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Figure 55: Effect of GemcitabineLinkerPenetratin and GemcitabineLinkerpVEC conjugates and free gemcitabine on the growth 
of different human tumoral cell lines evaluated by Sulforhodamine B assay. Cells were treated with a broad concentration range (6.3  
100.0 µM) of each compound for 48 h. Each value represents the mean ± SEM (n = 3  6). **p <0.001, ***p <0.0001 (significant 
decrease vs control).  
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RESULTS AND DISCUSSION 
The Gemcitabine-CPP conjugates synthesized in this work were designed to act as new 
prodrugs of this chemotherapeutic agent, mainly by increasing the delivery of gemcitabine inside 
cells, where enzymatic hydrolysis will yield free gemcitabine, capable of inhibiting DNA synthesis. 
After analyzing the results of this initial screening of biological activity, there are some 
preliminary conclusions can be taken: (a) GemcitabineLinkerpVEC conjugate displays an effect 
on cell viability comparable to free gemcitabine, (b) GemcitabineLinkerPenetratin can reduce cell 
viability to a more significant extent than the other compounds, although in the highest 
concentration tested (100 µM), this conjugate is close to cytotoxicity limits, and (c) Gemcitabine 
seems to have a greater activity in cells originated from the human colon than from the human 
stomach. 
However, this study only gave the first insight into these conjugates activity in vitro and a more 
exhaustive understanding of these conjugates behavior, both in vivo and in vitro, is of major 
importance.  
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4. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
At the end of this dissertation project, it can be concluded that all of the proposed goals were 
accomplished. Both Cys-Penetratin and Cys-pVEC peptides were successfully synthesized by 
MW-SPPS with excellent purity, after the manual synthesis approach proved ineffective. This 
showed the importance of the heat provided by the microwave radiation to successfully synthesize 
these particular peptides. 
Gemcitabine was also modified to bare a thiol group (compound 4) or a dithiopyridine group 
(compound 7) and was successfully conjugated to both CPPs. GemcitabineLinkerPenetratin and 
GemcitabineLinkerpVEC conjugates were obtained with an excellent purity grade and with 
acceptable yields. 
The conjugates stability studies demonstrated a different gemcitabine release profile for the two 
conjugates, with GemcitabineLinkerpVEC yielding free gemcitabine exponentially and after a 
short period of time, with more than 50% of gemcitabine being detected after 48 h, while 
GemcitabineLinkerPenetratin is more stable under the tested physiological conditions. Also, the 
preliminary in vitro assays on the antiproliferative activity of the conjugates indicated that cells 
treated with the GemcitabineLinkerPenetratin conjugate had greater growth inhibition 
percentages. 
 
So as to continue this project, the next steps will require an optimization of the experimental 
conditions to modify gemcitabine, as well as optimizing the necessary purifications. As for testing 
the biological activity of the conjugates, both normal cells and cells with higher specificity for 
gemcitabine should be used in the next assays. 
 
Overall, this investigation project proved to be a very promising new strategy/approach. In the 
future, different CPPs and different drugs could be conjugated in order to improve cancer (and 
even other diseases) treatments and diminish side effects. 
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6. SUPPLEMENTARY INFORMATION 
6.1. Stability studies  periodic HPLC analysis over 6 days 
6.1.1. GemcitabineLinkerPenetratin Conjugate 
 
Figure 56: Stability study of the GemcitabineLinkerPenetratin conjugate: HPLC analysis performed in the beginning of the study (0 
h). Chromatogram acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient 
mode (0  100%), for 30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
 
 
Figure 57: Stability study of the GemcitabineLinkerPenetratin conjugate: HPLC analysis performed after 24 h. Chromatogram 
acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 
30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
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Figure 58: Stability study of the GemcitabineLinkerPenetratin conjugate: HPLC analysis performed after 48 h. Chromatogram 
acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 
30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
 
Figure 59: Stability study of the GemcitabineLinkerPenetratin conjugate: HPLC analysis performed after 72 h. Chromatogram 
acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 
30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
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Figure 60: Stability study of the GemcitabineLinkerPenetratin conjugate: HPLC analysis performed after 144 h. Chromatogram 
acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 
30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
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6.1.2. GemcitabineLinkerpVEC Conjugate 
 
Figure 61: Stability study of the GemcitabineLinkerpVEC conjugate: HPLC analysis performed in the beginning of the study (0 h). 
Chromatogram acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode 
(0  100%), for 30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
 
Figure 62: Stability study of the GemcitabineLinkerpVEC conjugate: HPLC analysis performed after 24 h. Chromatogram 
acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 
30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
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Figure 63: Stability study of the GemcitabineLinkerpVEC conjugate: HPLC analysis performed after 48 h. Chromatogram 
acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 
30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
 
Figure 64: Stability study of the GemcitabineLinkerpVEC conjugate: HPLC analysis performed after 72 h. Chromatogram 
acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 
30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
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Figure 65: Stability study of the GemcitabineLinkerpVEC conjugate: HPLC analysis performed after 144 h. Chromatogram 
acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 
30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
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6.2. Stability of the GemcitabineLinkerPenetratin conjugate  
periodic HPLC analysis over 22 days 
 
Figure 66: Stability study of the GemcitabineLinkerPenetratin conjugate: HPLC analysis performed in the beginning of the study 
(0 h). Chromatogram acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient 
mode (0  100%), for 30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
 
Figure 67: Stability study of the GemcitabineLinkerPenetratin conjugate: HPLC analysis performed after 7 days. Chromatogram 
acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 
30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
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Figure 68: Stability study of the GemcitabineLinkerPenetratin conjugate: HPLC analysis performed after 14 days. Chromatogram 
acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 
30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
 
 
Figure 69: Stability study of the GemcitabineLinkerPenetratin conjugate: HPLC analysis performed after 22 days. Chromatogram 
acquired with a HPLC-DAD system, with a C18 column, using ACN in water with 0.05% TFA as eluent, in gradient mode (0  100%), for 
30 minutes, at a flow of 1 mL/min and detection at ! = 220 nm. 
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6.3. LC-MS chromatograms of the CPPs and the conjugates 
 
 
Figure 70: LC-MS chromatogram of the Cys-Penetratin peptide, synthesized in the CEM Liberty1 MW assisted peptide synthesizer. 
 
 
Figure 71: LC-MS chromatogram of the Cys-pVEC peptide, synthesized in the CEM Liberty1 MW assisted peptide synthesizer. 
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Figure 72: LC-MS chromatogram of the GemcitabineLinkerPenetratin conjugate. 
 
 
Figure 73: LC-MS chromatogram of the GemcitabineLinkerpVEC conjugate. 
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